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Chronic obstructive pulmonary disease (COPD), a progressive and nonreversible disease, 
is a leading cause of mortality and morbidity throughout the world. Detecting COPD 
early in the disease process will help in decreasing later stage COPD severity. Because 
airway inflammation is a hallmark of COPD, it has been proposed that measuring exhaled 
nitric oxide, a marker of inflammation, in exhaled breath condensate could prove to be an 
inexpensive and efficient method to detect COPD in outpatient settings.  Using the 
hypothetico-deductive theory as a guideline, this study used secondary data from the 
National Health and Nutrition Examination Survey 2007 to 2010 to test the association 
between exhaled nitric oxide (eNO), COPD, and COPD severity. In addition, this study 
explored whether occupation modifies the association between eNO and COPD. 
Descriptive statistics, chi-square analyses, and regression analyses were used to analyze 
data from a sample size of 10,214 individuals. The prevalence of COPD was 7.2%, based 
on self-reported physician diagnoses and 11.4% based on prebronchodilator spirometry 
analysis, strengthening the argument that COPD is often under- or misdiagnosed in 
clinical settings.  This study found no statistically significant association between eNO, 
COPD, and COPD severity, and occupational status did not appear to modify the 
association between eNO and COPD.  The findings of this study highlight the importance 
of using objective measures such as spirometry in clinical settings for early diagnosis and 
management of COPD. Early diagnosis helps to slow the progression of the disease, 
resulting in fewer related comorbidities and complications.  
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Chapter 1: Introduction to the Study 
Background of the Study 
Chronic Obstructive Pulmonary Disease (COPD) is a leading cause of mortality 
and morbidity throughout the world.  While many medical causes of death are 
decreasing, COPD is on the rise.  In 2005, 5% of all deaths worldwide were due to COPD 
complications (World Health Organization, 2011). This percentage is predicted to 
increase by 30% by 2020, and COPD is on target to become the third leading cause of 
death worldwide (World Health Organization, 2011).  
COPD comprises two subgroups of disease: chronic bronchitis and emphysema. 
Since there is no cure for COPD, the focus is on early diagnosis, treatment, and 
prevention. The two main methods for diagnosing COPD are spirometry and sputum 
induction tests.  Spirometry determines lung function as a ratio of expired air and lung 
function, and the sputum test analyzes bacteria and fungi to help establish the stage of the 
disease.  Although both are considered noninvasive, neither is suited for outpatient 
testing. Sputum induction is too time-consuming—it takes 30 to 45 minutes to complete, 
requires a lab analysis, and depends upon the patient’s ability to produce a sputum 
sample at the time of testing.  Spirometry testing requires a trained medical professional 
to administer and read the results.  One promising technique for use in outpatient settings 
measures is exhaled breath condensate (EBC) using GC-MS, eNose, or similar methods. 
The advantage of these methods is that mediators found in exhaled breath, such as 
exhaled nitric oxide (eNO), may correlate with airway inflammation and disease 
progression in COPD. If eNO is associated with COPD, then methods could be 
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developed to test eNO in outpatient settings, providing public health professionals an 
important and inexpensive tool to diagnose the type and possibly level of COPD severity. 
Airway inflammation is a hallmark of COPD and asthma.  Nitric oxide (NO) is 
naturally produced in the body and helps fight inflammation. Elevated NO levels 
observed in the EBC of asthmatic patients are used to diagnose and manage asthma in 
clinical settings (Djukanovic & Gadola, 2008). However, the role eNO plays in COPD is 
inconclusive, with some studies finding a positive correlation (Brindicci et al., 2005), 
others reporting a negative association (Beg, Alzoghaibi, Abba, & Habib, 2009), and 
some finding none (Bazeghi, Gerds, Budtz-Jørgensen, Hove, & Vestbo, 2011).  This 
study took a different approach from current research and analyzed combined data from 
NHANES 2007–2008 and 2009–2010 to determine associations between eNO, COPD 
(chronic bronchitis or emphysema), and COPD severity.  Patients’ occupations are 
seldom reported in the current literature examining the association between eNO and 
COPD (Bazeghi et al., 2011; Bhowmik, Seemungal, Donaldson, & Wedzicha, 2005; 
Brindicci et al., 2005; Lehouck, Carremans, De Bent, Decramer, & Janssens, 2010; Liu, 
Sandrini, Thurston, Yates, & Thomas, 2007). Therefore, in this study, I also examined 
whether occupation modifies the association between eNO and COPD. More information 
is provided in Chapter 2. 
Problem Statement 
  COPD is often under- or misdiagnosed in the primary care setting (Jochmann et 
al., 2010; Lehouck et al., 2010; Smidth, Sokolowski, Kærsvang, & Vedsted, 2012; 
Spyratos, Chloros, & Sichletidis, 2012). Spirometry, the current gold standard for 
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diagnosing COPD, is often underutilized or used incorrectly (Spyratos et al., 2012).  
Therefore, a noninvasive method to diagnose COPD in primary care settings is needed. 
NO analysis from EBC is a promising technique which is quick, easy to use, and highly 
reproducible (Beg et al., 2009). 
NO and NO derivatives are known markers of airway inflammation present in 
EBC of asthma patients. However, studies on the correlation between NO derivatives, 
airway inflammation, and COPD severity are inconclusive; some have shown an 
association between eNO and COPD (Beg et al., 2009; Brindicci et al., 2005), whereas 
others have not (Bazeghi et al., 2011). If eNO levels correlate with inflammation and 
COPD severity, their measurement would allow public health and clinical professionals 
to use eNO levels to quickly diagnose COPD severity in outpatient settings. This method 
is noninvasive and requires less time and expertise than either sputum induction tests or 
spirometry. Public health professionals agree that a noninvasive method based on EBC is 
needed for outpatient settings (Fens et al., 2009; Holz et al., 2008).  Associating eNO 
with airway inflammation in COPD would be a step in that direction. 
Purpose of the Study 
The purpose of this quantitative study was to determine if there is an association 
between eNO, COPD subgroups, and COPD severity, using the NHANES 2007 to 2010 
data. In addition, I explored effect modification by occupational status.  COPD and 
COPD severity, as defined by the Global Initiative for Lung Disease (GOLD) standard, 
were dependent variables. Exhaled NO was the independent variable. Exhaled NO is a 
marker for inflammation in exhaled breath condensate for asthma, but has not been 
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proven conclusively to be a marker for airway inflammation in COPD studies. As 
previously stated, Beg et al. (2009) and Brindicci et al. (2005) have shown a correlation, 
and Bazeghi et al. (2011) showed none. (Detailed information on these and other studies 
is presented in Chapter 2.) One major limitation of past studies was low sample size:  the 
average sample size was 80 (range: 20 to 176) with an average of 53 COPD participants 
in each study (range: 14 to 91).  A second limitation is that no researchers have yet 
examined the possible modifying role of occupational status upon both eNO and COPD.  
NHANES collected information on self-reported chronic bronchitis and emphysema and 
measured FEV1, FVC, and eNO from a large representative sample during its 2007 to 
2010 data collection cycles. The presence of these data along with self-reported 
occupational history provided the opportunity to study the association between eNO, 
COPD, and COPD severity in a single study.  The measurement of eNO in EBC is 
noninvasive and quick and easy to perform. If it is positively correlated with COPD, it 
has the potential to replace sputum tests for diagnosis and management.    
Theoretical Framework 
This dissertation was guided by the hypothetico-deductive theory, which is based 
on formulating and testing a hypothesis or hypotheses by deduction analysis (Ludan, 
1982). These deductions are tested in controlled experiments. Hypotheses that are 
falsified are rejected and replaced by new hypotheses.  The hypothetico-deductive theory 
has been around for hundreds of years and tested and debated by such historical figures 
as Rene Decartes, David Hume, and Issac Newtown (Ludan, 1982). Detailed information 
on the theoretical framework is presented in Chapter 2. 
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Research Questions and Hypotheses 
I examined the associations between eNO, COPD, and COPD severity and the 
effect of the role of occupation on these associations. The research questions and the 
hypotheses for the study were as follows:   
 Research Question 1: Is there an association between eNO and COPD (chronic 
bronchitis or emphysema) in adults? 
o Hypothesis 1: There is an association between eNO and self-reported, 
physician-diagnosed COPD (defined as presence of chronic bronchitis or 
emphysema) among adult NHANES 2007 to 2010 participants.   
o Hypothesis 2: Increasing eNO levels are associated with increased COPD 
severity, as defined by the GOLD standard.   
 Research Question 2: Does occupation modify the association between eNO and 
COPD?   





Definition of Terms 
 Chronic Obstructive Pulmonary Disease (COPD): COPD is a slowly progressive, 
preventable, treatable heterogeneous, multiphenotypic disease that is 
characterized by limitations of airflow due to inflammation that are not fully 
reversible and not curable (Basanta et al., 2010; Ferrara, 2011; Garvey, 2011; 
WHO, 2011). Alternative names for COPD include chronic obstructive airway 
disease, chronic obstructive lung disease, chronic bronchitis, emphysema, and 
bronchitis chronic (MedlinePlus, 2011).  However, chronic bronchitis and 
emphysema are the major forms of COPD. 
 Exhaled breath condensate (EBC) collection: EBC collection is a noninvasive 
means to collect breath samples from the lungs.  There are many types of 
mediators within the lungs that are causes of disease and can be regulated by 
therapeutics (Horváth et al., 2005). 
 Global Initiative for Chronic Obstructive Lung Disease (GOLD): The GOLD 
standard defines four stages of COPD ranging from mild (Stage I) to severe 
(Stage IV).  Each stage is characterized by the airflow limitations calculated by 
spirometry.  A patient classified as Stage I may not be able to sense an abnormal 
airflow, whereas a person with Stage IV may have chronic respiratory failure and 
terminal exacerbations.  More information is given in Table 4. 
 Nitric Oxide (NO): There are several derivatives of NO.  Fractional exhaled nitric 
oxide (FENO) in exhaled breath allows public health professionals to assess 
airway inflammation. Other derivatives include alveolar nitric oxide concentration 
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(CalvNO) and bronchial nitric oxide concentration (JawNO) (Lehouck et al. 
2010). I use exhaled nitric oxide (eNO) to represent exhaled nitric oxide, 
including FENO. 
 Spirometry: This method compares the amount of air a person can forcibly exhale 
in the first second of one breath (FEV1) with the amount of total air exhaled in 
one breath (FVC). The normal FEV1/FVC ratio is 70 to 80% (GOLD, 2010). 
 Sputum induction: This is a noninvasive method in which sputum (a combination 
of mucus and saliva) is expelled from the lungs with the help of a nebulizer.  The 
sputum is then collected and analyzed for disease biomarkers (Grant, Hammitt, 
Murdoch, O'Brien, & Scott, 2012). 
Assumptions and Limitations 
The NHANES public use data were used in the study, and it was assumed that the 
sample is representative of noninstitutionalized adults in the United States.  It was further 
assumed that the data—self-reports, FEV1, FVC, and eNO—were collected according to 
the established guidelines without any measurement error. Lastly, it was assumed that 
eNO levels reflect true underlying airway inflammation.   
One of the limitations of this study is that self-reported data from the interviews 
may be subject to recall bias. This bias may be introduced into the study if the patients do 
not accurately recall reporting information related to certain confounding variables 
affecting NO levels, such as eating nitrogen-rich foods, smoking, and taking medications.  
In addition, misclassification bias due to measurement error in administering the 
spirometry and measuring eNO is also possible. However, it is believed that this bias was 
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minimized by the rigorous collection and recording procedures adopted by the NHANES 
survey. Lastly, self-reported occupation data did not have sufficient detail to determine 
the potential or actual amount of occupational exposure to harmful particles, gases, and 
fumes to quantify eNO.    
Significance of the Study 
The study has several positive public health implications.  The first is that COPD 
is often misdiagnosed or underdiagnosed in primary care settings (Jochmann et al., 2010; 
Lehouck et al., 2010; Smidth et al., 2012; Spyratos et al., 2012).  Early diagnosis can 
slow or stop the disease progression by convincing the patient to alter habits, behaviors, 
or lifestyle, such as quitting smoking (Jochmann et al., 2010; Minas et al., 2010). 
Currently there is no noninvasive technique that is quick and easy to use in outpatient 
settings. The availability of noninvasive diagnostic methods could help field medical 
professionals such as those in mobile health units to reach out to the underserved 
population, especially in developing countries, to provide and monitor medical care. 
Early diagnosis of COPD could help decrease the incidence and prevalence of later stage 
COPD and ultimately could decrease comorbidities and mortality rates caused by COPD.  
Measuring eNO in EBC is a promising noninvasive method that would allow 
physicians and public health professionals to monitor the progression of COPD in 




Implications for Social Change 
The implications for positive social change were that individuals can be 
diagnosed with a noninvasive method more quickly and safely than with traditional 
methods.  Used in preventative screenings, such a method could result in early diagnosis 
and treatment to prevent the severe later stage forms of COPD.  Patients’ quality of life 
will increase, associated comorbidities will decrease, and mortality rates will decline.    
Summary and Transition 
Sputum induction is the current gold standard for determining phenotypes of 
COPD. However, sputum induction is too time-consuming and labor intensive for use in 
outpatient settings.  Researchers agree that a new noninvasive method is needed for the 
clinical setting (Jochmann et al., 2010; Lehouck et al., 2010; Smidth et al., 2012; 
Spyratos et al., 2012). Although gas chromatography–mass spectrometry (GC-MS), 
electronic noses (eNoses), and similar devices can differentiate between different 
respiratory diseases such as asthma and COPD, there is no current EBC diagnostic 
technology that can uncover COPD heterogeneity.  In addition, studies correlating eNO 
to inflammation and COPD severity have been inconclusive as seen in conflicting results 
from several studies (Bazeghi et al., 2011; Brindicci et al., 2005). 
Therefore, in this study, I attempted to improve upon past research by analyzing 
eNO levels and comparing them with diagnoses of chronic bronchitis and emphysema 
and documented levels of severity in a larger sample size obtained through NHANES 
data from 2007 to 2010.  In addition, through the second research question, I investigated 
whether the association between eNO and COPD is modified by occupation.  If eNO 
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levels are correlated with airway inflammation in different forms of COPD subgroups 
and severity, the measurement of eNO could be used to develop methods for EBC testing.  
This could lead to more patients tested in outpatient settings as a preventive measure and 
eventually could lead to early treatment that would result in a decrease in later-stage 
COPD cases and COPD-related comorbidities, lower healthcare costs, and eventually a 
decrease in COPD-related mortality.   
In Chapter 2, I review the literature related to eNO and COPD and outline the 
theoretical framework of this study. The GOLD standard, spirometry, and the role of 
occupation are also discussed.  Chapter 3 outlines the research methodology; describes 
the dependent, independent, and confounding variables; and explains the statistical 
analysis. The results of this study are reported in Chapter 4, and the summary, discussion, 
and conclusions are presented in Chapter 5.      
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Chapter 2: Literature Review 
Background 
 Current methods for diagnosing COPD in the primary care setting, such as 
spirometry are underutilized, attributing to the misdiagnoses of COPD in primary care 
(Jochmann et al., 2010; Lehouck et al., 2010; Smidth et al., 2012; Spyratos et al., 2012).  
Therefore, a noninvasive method that is quick and easy to use is needed. A promising 
technique is analyzing eNO from EBC. The rationale is that airway inflammation is 
found in all forms of COPD.  NO and NO derivatives are known markers of airway 
inflammation present in EBC.  Research has shown a correlation between eNO and 
inflammation in asthma patients. However, there is no conclusive association between 
NO derivatives, airway inflammation, and COPD severity. Therefore, the purpose of this 
study was twofold. The first objective was to investigate the association between eNO 
and COPD and eNO and COPD severity using NHANES data from 2007 to 2010. The 
second was to investigate whether the association between eNO and COPD is modified 
by occupation. This study used a larger sample size than previous studies and compared 
eNO, COPD (emphysema, chronic bronchitis), and COPD severity, where most recent 
research has focused on eNO and COPD or eNO and COPD severity, not both (Beg et al., 
2009; Brindicci et al., 2005; Liu et al., 2007). In addition, I investigated whether the 
association between eNO and COPD is modified by occupation. 
 I begin this chapter with reviewing basic information on COPD including 
prevalence and incidence, causes, at-risk population, diagnosis, mortality, and costs. 
More detailed information follows, with sections on epidemiology; risk factors ranging 
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from tobacco use to genetics; symptoms; and exacerbations.  I continue with detailed 
sections on methods for diagnosis such as sputum induction, spirometry, and EBC. I 
conclude with general information on NO leading into a more detailed discussion on the 
association between eNO and COPD (chronic bronchitis, emphysema), eNO and COPD 
severity, and NO from occupational exposure.  Table 1 gives the key databases used, and 
Table 2 lists key search terms. 
 Literature Search Strategy 
Table 1  
Key Databases Used 
Key Databases Used 
Walden University Library – Thoreau 
Walden University Library – Medline with Full Text 
Walden University CINAHL Plus with Full Text 
Google: Google Scholar 





Table 2   
Key Search Terms 
Search terms 
 
 Chronic Bronchitis  Nitric, COPD, NHANES 
 Chronic Obstructive Pulmonary 
Disease  
 Nitric, Job 
 Chronic Obstructive Pulmonary 
Disease, by country 
 Nitric, Occupation 
 Chronic Obstructive Pulmonary 
Disease, Costs 
 Nitric, Work 
 Chronic Obstructive Pulmonary 
Disease, EBC  
 Nitric Oxide 
 Chronic Obstructive Pulmonary 
Disease, Epidemiology EBC 
 Nitric Oxide, Inflammation 
 Chronic Obstructive Pulmonary 
Disease, Specific Author Name   
Exhaled Breath Condensate 
 Nitric Oxide, Job 
 COPD   Nitric Oxide, NHANES 
 COPD, Costs  Nitric Oxide, Occupation 
 COPD, EBC  Nitric Oxide, Work 
 COPD, Europe  Nitric Oxide, Specific Author Name 
 COPD, Exhaled Breath Condensate  NO, COPD, Job 
 COPD, NHANES  NO, COPD, Occupation 
 COPD, NO, NHANES  NO, COPD, Work 
 Diagnosis, COPD  NO, Inflammation 
 Diagnosis, Chronic Obstructive 
Pulmonary Disease 
 NO, NHANES 
 Emphysema  NO, Nitric 
 Epidemiology COPD, Specific 
Author Name 
 NO, Specific Author Name 
 GOLD, Chronic Obstructive 
Pulmonary Disease 
 Specific Author Name 
 GOLD, COPD  Specific Title of a Paper 
 NHANES, Nitric, COPD, 
Occupation 
 Spirometry 
 NHANES, Nitric, COPD, Job  Sputum Induction 





Scope of Literature 
 
The literature collected was published from 1995 to 2014. Research from 1995 to 
2005 was used to provide a historical background and to frame the problem. Most data 
came from recent literature dating from 2005 to 2014. Assessing the link between eNO 
and COPD is a relatively new topic, and current literature was limited in the number and 
size of the studies. Literature included in this study is from peer-reviewed sources, 
scholarly articles, periodicals, journals, textbooks, websites, interviews, conferences, and 
Internet sources. Table 3 gives examples of literature collected and analyzed for this 
paper.  
Table 3  
Literature Included 
Sources Examples 
Conferences Breath Summit 2011 
Internet sources Center for Disease Control, World Health 
Organization 
 
Interviews Dr. Susan Hausserman 
Journals, peer-reviewed sources, 
Periodicals 
American Journal of Respiratory Care 
Medicine 
Scholarly articles Journal of Breath Research 
Textbooks Health promotion planning and evaluation:  







The hypothetico-deductive theory is based on formulating and testing a 
hypothesis or hypotheses by deduction analysis. Deductions are tested by observations 
and experiments. Hypotheses that are proven false are rejected and replaced by new 
hypotheses (Oreskes, 2003).  Figures 1, 2, and 3 are visual representations of the three 





            
            
            
            
            
            










Figure 1.  Hypothesis 1: There is an association between eNO and COPD (chronic 
bronchitis and emphysema). 
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Figure 2. Hypothesis 2: Increasing eNO levels are associated with increased COPD 












Figure 3.  Hypothesis 3 – The association of eNO and COPD is modified by occupational 
exposure.  
 
Exhaled NO is a determinant of airway inflammation in asthma, and airway 
inflammation is prevalent in all stages of COPD.  Therefore, eNO may be a determinant 
of airway inflammation for COPD, and eNO could be used as a noninvasive biomarker to 
diagnose COPD.  This is important, because this is a noninvasive, easy-to-use method 
that could replace more invasive tests. 
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Figure 1 
COPD Severity (Stage I) 
COPD Severity (Stage II) 
COPD Severity (Stage III) 
COPD Severity (Stage IV) 
At-Risk 
Not At- Risk 
Occupational Exposure 
to Nitric Oxide 





 The independent variable was eNO. The first hypothesis stated that eNO was 
associated with COPD. The second hypothesis stated that there is an association between 
eNO and COPD severity as categorized by the GOLD standard. Exhaled NO is a known 
marker for airway inflammation in asthma, but its role in COPD is inconclusive. Through 
the second research question, I investigated whether occupation modified the association 
between eNO and COPD.  
Introduction 
COPD is a global disease contributing to an increase in morbidity and mortality 
while causing higher medical costs and social economic burdens (Budweiser et al., 2007; 
Rocker, Young, & Simpson, 2009; Tonello & Poli, 2011).  In 2002, COPD was the fifth 
leading cause of death (Tonello & Poli, 2011; World Health Organization, 2011). In 
2004, COPD affected approximately 64 million people (World Health Organization, 
2011). In 2005, 5% of deaths worldwide (3 million people) resulted from COPD (World 
Health Organization, 2011). Ninety percent of COPD-related deaths were in low-income 
to middle-income countries (World Health Organization, 2011). Total deaths are 
expected to rise by 30% over the next decade if there are no interventions. Furthermore, 
COPD is expected to become the third leading cause of death globally by 2020 (Bessa et 
al., 2011; Rocker et al., 2009; World Health Organization, 2011). This projected increase 
in mortality is due to the aging of the world’s population and the continued use of 
tobacco (Malipatil & McDonald, 2009).  In Western societies, many medical causes of 
death are on the decline; however, the prevalence of morbidity and mortality of COPD in 
both men and women is increasing (Rocker et al., 2009).    
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COPD is a noncurable, slowly progressive, preventable but treatable 
heterogeneous, multiphenotypic disease that is characterized by limitations of airflow due 
to inflammation (Basanta et al., 2010; Garvey, 2011; World Health Organization, 2011).  
Alternative names for COPD include chronic obstructive airway disease, chronic 
obstructive lung disease, chronic bronchitis, emphysema, and bronchitis chronic 
(MedlinePlus, 2011).  However, chronic bronchitis and emphysema are the two dominant 
forms of COPD, and most people have a combination of the two. 
COPD is not fully reversible, and therefore the focus is not on curing the disease, 
but on diagnosis, prevention, and treatment.  Two major risk factors for COPD include 
tobacco smoke and air pollutants (Hoth, Wamboldt, Bowler, Make, & Holm, 2011). For 
example, in the United States, smoking played a role among 80% to 90% of COPD 
patients (Hoth et al., 2011).  Although COPD is prevalent in smokers, research has shown 
that nonsmokers can also develop it because of genetic disposition (Nazir & Erbland, 
2009). Studies have determined that mutations of a specific gene may cause COPD in 
nonsmokers (Nazir & Erbland, 2009). COPD affects the entire body, including the heart, 
kidneys, and muscles, and is associated with a large range of comorbidities, such as 
cardiovascular disease, osteoporosis, and diabetes (Lynes, 2010).  In addition, there are 
emotional consequences of having COPD, as the patient’s quality of life (QoL) is 
adversely affected.  For example, individuals with COPD may experience difficulties in a 
wide range of areas in their life, resulting in early retirement, financial stress, family 
complications, changes in self-esteem, and lack of independence (Avsar & Kasikci, 
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2010). In addition, recent studies have demonstrated that oxidative stress is a key risk 
factor in the pathogenesis of COPD (Lee & Thomas, 2009). 
COPD is a major contributor to death, disability, and financial burdens throughout 
the world. As the population ages, COPD will continue to contribute to economic 
hardships for several years (Hutchinson, Brand, Irving, Roberts, & Campbell, 2010).  As 
the prevalence and incidence rates of GOLD Stages III and IV increase, compared to 
Stages I and II, the costs of COPD management will also increase. The advanced stages 
of the disease consume a large proportion of health care resources due to excessive 
hospitalizations, exacerbations, and mortality rates (Budweiser, Jorres, & Pfeifer, 2008).   
Early diagnosis and treatment are key to controlling and decreasing COPD 
incidence and prevalence rates.  Currently, lung performance is assessed by spirometry, 
which is accepted as a universal method, by public health professionals worldwide, to test 
for COPD.  This method measures the ratio of FEV1 to FVC. A healthy person has an 
observed ratio of greater than or equal to 70% lung capacity.  Individuals with a ratio of 
less than 70% are considered to have some form of COPD (GOLD, 2010). The GOLD 
standard lists four stages of COPD, with Stage I defined as mild COPD, and Stage IV as 
very severe (see Table 4).  Due to the slow progressive nature of the disease, COPD is 
more frequently diagnosed in individuals over 40 years of age (World Health 
Organization, 2011).  However, many forms of treatment are available to aid in managing 
symptoms and increasing QoL. Pharmacotherapy targeted at COPD includes the use of  
bronchodilators, corticosteroids, antibacterial products, and/ or a mix of these 
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pharmaceuticals (Nazir & Erbland, 2009).  Table 4 gives the criteria for COPD severity 
when tested by spirometry.  
Table 4  
GOLD Spirometry Criteria for COPD Severity 
Severity Characterized by airflow 
limitation 
Criteria 
Mild (I) FEV1/FVC < 0.70, FEV1 
>= 80 % predicted 
At this stage, the patient 
may not be aware that their 
lung function is abnormal. 
Moderate (II) FEV1/FVC < 0.70, 50 % 
<= FEV1 <= 80 % 
predicted 
Symptoms usually progress 
at this stage, with shortness 
of breath typically developing 
on exertion. 
 
Severe (III) FEV1/FVC < 0.70, 30 %  
<= FEV1 <= 50 % 
predicted 
Shortness of breath typically 
worsens at this stage and 
often limits patients’ daily 
activities. Exacerbations are 
especially seen beginning at 
this stage. 
Very Severe (IV) FEV1/FVC < 0.70, <30 
% predicted or  FEV1 
<50 % predicted plus 
chronic respiratory 
failure 
At this stage, quality of life 
is very appreciably impaired 
and exacerbations may be 
life-threatening. 
 
Note.  Global Initiative for Chronic Obstructive Lung Disease. (2010). Spirometry for health care providers: Global Initiative for 
Chronic Obstructive Lung Disease (GOLD). from http://www.goldcopd.org/uploads/users/files/GOLD_Spirometry_2010.pdf 
 
 
COPD is underdiagnosed around the world (Jochmann et al., 2010; An Lehouck 
et al., 2010).  For example, in the United States, for every one person diagnosed with 
COPD, there are another 1.4 people who have not been diagnosed and therefore not 
captured in healthcare statistics (Garvey, 2011).  Concerning healthcare utilization in the 
United States, in 2000 there are approximately 8 million primary care provider and 
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outpatient visits, 1.5 million emergency room visits and 726,000 hospitalizations due to 
COPD (Garvey, 2011). In addition, 1 in 5 elderly in the United States are hospitalized 
because of COPD (Avsar & Kasikci, 2010; Malipatil & McDonald, 2009).  Estimated 
annual COPD rates in other countries are 2.7 million in Germany, 300,000 in Australia, 
200,000 in New Zealand, and 1.5 million in Spain (Avsar & Kasikci, 2010).   
In 2005, COPD caused 126,005 deaths in the United States in persons 25 years 
and older.  This represented an 8% increase from 116,494 in 2000 (Caress, Luker, & 
Chalmers, 2010).  The United Kingdom estimates that there are between 25,000 and 
30,000 COPD-related deaths per year (British Lung Foundation, 2011; Health and Safety 
Executive, 2013). Approximately 15% of those admitted with COPD die within the 
following 3 months, and 25% within 1 year of admission (British Lung Foundation, 
2011; Trueman & Trueman, 2011). 
Healthcare costs related to COPD have a significant impact throughout the world.  
In 2001, 520 patients were admitted to UK hospitals. This equates to 4,156 beds or £1.13 
million  In Spain, 43.8% of all hospitalization costs and 40.3% of drug acquisition costs 
are related to COPD (Banning, 2006).  The cost of treating patients with exacerbated 
COPD by the Canadian Healthcare system was approximately $750 million per year 
(Rocker et al., 2009).  A study on the economic burden in the United States concluded 
that the cost per patient was between $2,700 and $5,900 per patient annually.  In-patient 
hospitalization accounted for close to 70% of all direct costs.  One study estimates the 
total costs due to COPD in the United States  at $10 billion per year (Rocker et al., 2009). 
Another estimates direct costs of COPD at $29.5 billion and indirect costs at $20.4 billion 
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(GOLD, 2010). The healthcare cost for people with COPD are more than double of those 
of age-matched peers (Rocker et al., 2009). In Europe, 6% of total healthcare costs are 
related to respiratory diseases (Spyratos et al., 2012). COPD accounts for 50% of those 
costs—38.6 billion euros per year(Spyratos et al., 2012). 
The COPD drug market is estimated to increase from approximately $8.4 billion 
in 2009 to more than $13 billion in 2019 in the US, France, Germany, Italy, Spain, UK, 
and Japan (Business Wire, 2011). Forecasters believe that an expanding aging population 
and improvements in diagnosis and drug treatment will drive market growth (Business 
Wire, 2011).  In addition, in the major pharmaceutical markets, the population that will 
rely on drug treatments will increase 75%, from 18 million patients in 2009 to 
approximately 24 million in 2019 (Business Wire, 2011). 
High healthcare costs are evident before COPD diagnosis. One study, a 
retrospective analysis of healthcare costs using matched cases and controls, determined 
that costs were $1,182 higher 24 months prior to diagnosis of COPD and $2,489 higher 
12 months before (Mapel et al., 2008).  United States’ data for 2001, showed 110,000 
deaths, 500,000 hospitalizations, and over $18 billion in direct medical expenditures 
annually as a result of acute exacerbations of COPD (Hutchinson et al., 2010). The 
implication is that these cost could be prevented or reduced with early diagnosis of 
COPD. 
Epidemiology/ Clinical - Demographics 
COPD is a slow, progressive disease that typically affects people 40 years old and 
older (World Health Organization, 2011).  Men and women are equally affected by 
23 
 
COPD. The World Health Organization attributes this to an increase in the incidence and 
prevalence in women smokers in high-income countries (World Health Organization, 
2011). A study using NHANES data from 1997 to 2004 showed a high incidence in 
young women (5.4% 95% CI: 5.3-5.6) compared to men (2.8% 95% CI: 2.7-2.9) 
validating the hypothesis that COPD is increasing among women (Bang, Syamial, & 
Mazurek, 2009). 
Emphysema and chronic bronchitis are the two dominant forms of COPD. 
Emphysema is the destruction of the lung over time by enlargement of and destruction of 
air sacs (Ferrara, 2011; MedlinePlus, 2011). Some causes for the enlargement include 
congenital defects, surgical procedures on the lung, or an infection (Ferrara, 2011).  The 
disease process itself centers around inflammatory injury to the lung due to abnormal 
immune response to products like the toxic particles in tobacco smoke, inhalation of 
environmental particulates, or occupational exposure to biomass fuel products in poorly 
ventilated areas.  A poor immune response causes the small air-exchange spaces in the 
lungs to expand and combine into larger, dysfunctional airspaces.  This results in a loss of 
function, a loss of lung elasticity, an increase in hyperinflation, and ultimately, a 
reduction of airflow in the lungs (Ferrara, 2011). There are several types of emphysema, 
such as panacinar emphysema and centrilobular emphysema, but each form displays the 
same destructive patterns (Ferrara, 2011).   
Bronchitis is the inflammation of the bronchial tubes.  The bronchial walls 
become permanently inflamed or thickened.  This creates a cough that produces mucus or 
phlegm.  Chronic bronchitis is a progressive disease that is defined by coughing at least 
24 
 
one time a day for 3 months.  Complications from chronic bronchitis include asthma, 
bronchectasis, cystic fibrosis, tuberculosis, and sinusitis. 
General Risk Factors 
Risk factors for COPD are outdoor air pollution and indoor air pollution, such as 
occupational dust and particulate irritants and chemical vapors and fumes (GOLD, 2010).  
Biomass fuels are a major contributor to COPD among nonsmoking women in countries 
like Africa and Asia, as well (World Health Organization, 2011). Individuals with 
frequent lower respiratory infections during childhood are at risk for COPD (GOLD, 
2010; MedlinePlus, 2011).  Genetics is also a factor in the rare cases of individuals who 
develop emphysema due to a lack of the protein alpha-1-antitrypsin (MedlinePlus, 2011). 
The metabolic and physiological changes of aging can influence efficacy and 
safety.  In order patients, the high prevalence of comorbidities such as cardiovascular 
disease and osteoporosis can reduce tolerance to COPD therapy. (Malipatil & McDonald, 
2009). In the Burden of Obstructive Lung Disease initiative, the prevalence of COPD 
GOLD Stage II or higher across 12 countries was 11.8% for men and 8.5% for women 
(Imperial College London, n.d.; Nazir & Erbland, 2009).  Results from this study showed 
that disease prevalence increases with age. Less than 5% of all persons aged 40 to 49 had 
COPD, but the incidence increased 19% to 47% and 6% to 33% in men and women, 
respectively, for those aged 70 and over (Nazir & Erbland, 2009). 
Another risk factor is exposure to certain environmental conditions during 
childhood.  Depending on the type of pollutant and the amount inhaled, children may 
have the same level of risk as smokers (Ferrara, 2011). In addition, maternal smoking has 
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been associated with the development of respiratory diseases (including COPD) in adults 
(Ferrara, 2011).   
COPD rates in the United States are inversely proportional to socioeconomic 
status, with blue-collar workers exhibiting higher degrees of mortality and morbidity 
rates than white-collar workers (Ferrara, 2011).  Individuals who work on a farm are 
constantly exposed to dust and are two to three times more likely to develop COPD than 
non-farm workers.  Coal miners also have an increased risk due to their working 
environment (Ferrara, 2011). These same disparities are apparent when comparing 
education and income (Ferrara, 2011). The risk of developing COPD during adulthood 
may be linked to lower socioeconomic status during childhood, resulting from to 
exposure to outdoor and indoor pollution (Nazir & Erbland, 2009).  
Genetic studies have looked at the association of polymorphism and COPD.  A 
meta-analysis study on 20 polymorphisms in 12 candidate genes showed that many genes 
were not linked to COPD. However, the study populations included in the sample 
influenced this result (Cosio & Agusti, 2010).  In addition, a study linking the C-reactive 
protein gene to COPD has been inconclusive.  Therefore, evidence linking genetic 
inheritance and COPD is currently inconclusive, and further research is needed (Cosio & 
Agusti, 2010). 
Symptoms 
Symptoms of COPD include abnormal sputum (a mixture of mucus and saliva the 
airway), breathlessness, and a chronic cough.  Other symptoms include mucus produced 
when coughing, shortness of breath (dyspnea) that worsens even with minimal activity, 
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presentation of respiratory infections, and wheezing (MedlinePlus, 2011). Daily activities 
like walking upstairs can become difficult as the disease worsens (World Health 
Organization, 2011). Other problems include increased anterior and posterior chest 
diameter—AKA “barrel chest”—caused by air trapping; cyanosis; nail clubbing: and the 
use of accessory muscles when breathing (Ferrara, 2011). COPD patients may not 
experience all of these symptoms.  For example, in one study 43% of patients did not 
produce sputum (Lynes, 2010; Zieliñski, Bednarek, & Group, 2001).  Since COPD is 
progressive, the disease is often undetected; patients are not aware that they are sick. The 
first indication of COPD may be when the symptoms worsen; increased quantities of 
sputum, sputum purulence, and shortness of breath (dyspnea) are signs that the patient 
has an exacerbation at a more advanced stage of the disease (Albertson, Louie, & Chan, 
2010; MedlinePlus, 2011; Stoloff, 2011).  More specifically, these are signs of acute 
exacerbations of chronic bronchitis (Albertson et al., 2010; Lynes, 2010; MedlinePlus, 
2011).  However, COPD is a heterogeneous disease and can be difficult to diagnosis. 
Exacerbation is an acute action resulting in a deviation in the individual’s 
dyspnea, cough, or sputum production from the norm and requires a change in regular 
treatment (Garvey, 2011; Nazir & Erbland, 2009).  Exacerbations of COPD decrease 
QoL and lung function (Garvey, 2011). These exacerbations are interconnected and are 
associated with increased morbidity, increased comorbidities, decreased physical health, 
and increased chances of premature mortality (Glaab, Vogelmeier, & Buhl, 2010).  
However, comparing clinical symptoms of different patients can be challenging, because 
there are no standard definitions of exacerbations (Glaab, Vogelmeier, & Buhl, 2010; 
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Nazir & Erbland, 2009). In addition, exacerbations can be underreported due to recall and 
selective bias by patients (Glaab et al., 2010). Contributors to acute exacerbations include 
exposure to air pollution from particulates of diesel, sulfur dioxide, ozone, and nitrogen 
(Nazir & Erbland, 2009). Other risk factors include age, decreases in FEV1, lung 
infection, and high frequencies of past exacerbations (Albertson et al., 2010; Nazir & 
Erbland, 2009).  Seventy-five percent of cases of acute exacerbations are caused by viral, 
bacterial, or mixed viral-bacterial changes (Albertson et al., 2010).  Research indicates 
that these exacerbations are semirandom.  This means that the exacerbations are 
unpredictable but tend to cluster in time. For example, after a patient is subject to a first 
exacerbation, then the chances of a second exacerbation are greatly increased (Cosio & 
Agusti, 2010).   
Methods for Diagnosis 
Due to the wide range of comorbidities and the progressive nature of COPD, 
researchers have focused on early diagnosis, prevention, and treatment.  There are 
invasive approaches to determine airway inflammation, such as bronchoscopy and 
brancholveolar lavage, but these have been complemented by or replaced by the 
noninvasive method of induced sputum analysis (more information in the next section).  
However, the limitations of the induced sputum method have led researchers to consider 
alternative methods, such as EBC sampling.  Current methods for testing airway 
inflammation include spirometry to analyze lung function and sputum induction to 
determine airway inflammation.  
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Spirometry is performed by having the patient blow into a handheld device that 
measures lung capacity. Trained medical personnel can interpret the test results directly 
without the patient having to exercise, draw blood, or be exposed to radiation 
(MedlinePlus, 2011).  This is one of the most important tests for determining COPD 
severity levels; it is both accurate and reliable (Garvey, 2011).  Even though the method 
is considered the gold standard for measuring COPD progression, the procedure is 
underused or used inconsistently in the clinical setting (Stoloff, 2011).  For example, 
several studies assessed the use of spirometry in patients hospitalized and then discharged 
with a diagnosis of COPD (Stoloff, 2011).  Only 31% of these patients were tested using 
spirometry over an 8-year period (Stoloff, 2011).  Studies in Germany, Switzerland, and 
Denmark found that spirometry testing was underutilized when diagnosing COPD, 
leading to the underreporting of the disease (Jochmann et al., 2010; Smidth et al., 2012).  
In addition, other countries with good healthcare such as the United States, Spain, and 
Italy, also reported under usage of spirometry (Spyratos et al., 2012). 
Spirometry is one of the most important analysis for the diagnoses of COPD.  The 
GOLD standard suggests a bronchodilator rate of FEV1/FVC < 70% diagnostic for 
COPD. A limitation is that the FEV1/FVC ratio naturally declines with age, and using a 
fixed ratio increases the risk of over-diagnosing COPD in the elderly. Factors 
contributing to over-diagnosis include reduced perception of airflow, tendency to 
attribute symptoms to aging process, and lack of spirometric testing (Malipatil & 
McDonald, 2009).  In clinical practice this risk is offset by underdiagnoses in older 
people (Malipatil & McDonald, 2009).   
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Sputum induction is a primary analytic tool for the study of airway inflammation 
(Djukanovic, 2000). Sputum culture is used to detect and identify bacteria or fungi that 
are affecting the lungs or breathing passages (WebMD, 2012; 2011). One of the benefits 
of using induced sputum is the safety of the method; it is easy to use given time but 
depends on the severity of the disease and the patient’s ability to produce sputum at home 
(Djukanovic, 2000; Holz et al., 2008). A second benefit is that sputum induction does not 
require expensive equipment and testing is generally reimbursed by insurance (Holz et 
al., 2008). Third, sputum induction results in a more representative sample of several 
proximal airways than other methods (Djukanovic, 2000).  Limitations include high 
levels of thick mucus in unprocessed sputum (Djukanovic, 2000).  Samples are of lower 
quality of induced sputum and smear slide samples provide only semiquantitative 
information (Holz et al., 2008). The induction process of sputum is not suited to the 
outpatient setting because the method is labor intensive, depending on the patient ability 
to produce sputum, and the method is time consuming (Holz et al., 2008).   
Spirometry is the current benchmark for determining COPD, and sputum 
induction can identify bacteria and/ or fungi affecting the lungs. However, there are 
limitations to both methods (Tables 5-6).  A promising area of research is using EBC to 
differentiate between different respiratory diseases and between phenotypes of the same 
disease. Two studies published in 2011 use EBC to differentiate COPD patients who 
were smokers from those who were nonsmokers.  An eNose was used in both studies to 
analyze EBC from patients. One study was able to differentiate between asthmatic 
patients and those with COPD but unable to identify different stages of COPD by EBC 
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alone (Holz, Zesiger, Lavaue-Mokhtari, Schuchardt, & Hohfeld, 2011). This study, which 
had a small sample size of 14 patients, concluded that evaluating exhaled breath profiles 
by eNose has the potential to become a widely used noninvasive diagnostic tool. In the 
same year another study, using 100 patients, was able to differentiate between COPD and 
non-COPD patients.  The study conducted in the Netherlands used 100 patients, a Tedlar 
bag sample collection system, and an eNose (Fens et al., 2011; Fens, Roldaan, 
Zwinderman, Bel, & Sterk, 2011).  However the conclusion also mentioned that a more 
sensitive method and further research is necessary to show phenotypic differences (Fens 
et al., 2011; Fens, Roldaan, Zwinderman, Bel, & Sterk, 2011).  Both 2011 studies state 
that EBC is a promising method for noninvasive analysis of some respiratory diseases.  
Other researchers have used a wide variety of tools to diagnose EBC—eNoses with 
varying sensitivities, ion mobility spectrometers, differential mobility spectrometry, GC-
MS, and gas sensory array technology, to name a few. With the exception of an eNose 
application published in 2009, none have been able to uncover the heterogeneity of 
COPD. The 2009 study (Velásquez, Durán, Gualdron, Rodriguez, & Manjarres, 2009) 
distinguished between phenotypes, but the results were subjective because the 
classification of phenotypes was done by a personal physician and were not reproducible.   
Exhaled Breath Condensate 
To date, researchers have identified more than 3,500 components (mixtures of 
gases and volatile organic compounds) in exhaled breath (Popov, 2011). Almost half of 
the volatile organic compounds originate from within the body, and approximately 200 
trace compounds can be detected and quantified in an average human breath (Popov, 
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2011). The compounds can vary due to diet or disease. One of the most well-known 
examples of breath analysis is ethanol analysis, used to check for alcohol consumption 
levels. Other successful clinical applications include linking NO levels to asthma and 
linking carbon monoxide to oxidative stress (Popov, 2011).  
Using EBC for collecting and analyzing biomarkers has several advantages—ease 
of use, noninvasiveness, the possibility of repeated sampling, and suitability for use with 
children and patients with severe disease (Koczulla et al., 2009).  In addition, samples can 
be collected in a portable device home (Koczulla et al., 2009).   
One limitation of using EBC for COPD determination is its variability in 
statistical analysis.  There are several algorithms used to draw correlations between EBC 
and respiratory diseases—specifically, asthma and COPD.  The results are more or less 
favorable depending on the algorithm used.  Therefore, researchers tend to use algorithms 
that portray the data in the best possible manner.  Standardization is necessary to be able 
to compare data from one study to another. A second limitation is that there is no 
standard or accepted method for EBC analysis.  Several techniques have been used, 
including various eNoses, mass spectrometers, combination GC-MS, ion mass 
spectrometers (IMS), proton transfer reaction–mass spectrometers (PTR-MS), and gas 
sensor arrays.  No one method out-performs the others, although PTR-MS and IMS show 
promise.  The limitation is that comparing data with different types of diagnostic devices 
is challenging without standardized methods.  This is further complicated when 
comparing different diagnostic equipment with different algorithms. A third limitation is 
the lack of standardization of a sampling technique.  Collection techniques range from 
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having the patient breathe one time into a Tedlar bag to sampling using PTR-MS, where 
the PTR-MS and the patient must be present at the same time and breath is collected over 
a given period of time, such as ten minutes.  The difficulty is in knowing which part of 
the lung (lower, middle, or upper regions) the air is coming from; breath profiles will 
vary depending on where the exhaled air originates.  A fourth limitation of the current 
literature is that many studies start with known diseased and healthy populations.  
Because of all these variations in sample selection, sampling technique, and analysis, 
cross–research validation is challenging. However, the initial results, regardless of 
algorithm, diagnostic analysis, or sampling technique, show promise that EBC might be 
able to diagnose severity in COPD patients.  Tables 5, 6, and 7 list the strengths and 
weaknesses of the three most widely used diagnostic techniques.  
Table 5  





Underused in clinical setting 
Used inconsistently in clinical setting 
Need trained medical personnel to interpret 
Results subjective 
Note. Adapted from Holz et al. (2008). Assessing airway inflammation in clinical practice—experience with spontaneous sputum 






Table 6  
Sputum Induction Strengths and Weaknesses 
Strengths 
Safety 
Ease of use 
Can be done at home 
Does not require a lot of equipment 
Weaknesses 
Unprocessed sputum contains abundant and    
thick mucus 
Provides only semiquantitative information 
Labor intensive for quantitative cell count 
Time consuming and not suited for outpatients 
Note. Adapted from Holz et al. (2008). Assessing airway inflammation in clinical practice - experience with spontaneous sputum 
analysis. Biomedical Central Pulmonary Medicine, 8, 5. doi: 10.1186/1471-2466-8-5 
 
Table 7  
Exhaled Breath Strengths and Weaknesses 
Strengths Weaknesses 
Noninvasive 
Suited for outpatients 
No trained staff required 
Easy to use  
Repeated sampling —Do not run out of 
air 
No universal sampling preparation standard 
Several algorithms 
Multiple diagnostic machines 
Not sensitive enough 
Note. Adapted from Holz et al.. (2008). Assessing airway inflammation in clinical practice —experience with spontaneous sputum 
analysis. Biomedical Central Pulmonary Medicine, 8, 5. doi: 10.1186/1471-2466-8-5 
 
Because each of these techniques has practical limitations, researchers are continuing to 
test different methods and compounds in EBC in relation to COPD. One compound of 
particular interest is NO, because NO is linked to airway inflammation in asthma. 
Considering that airway inflammation is found in all stages of COPD, NO may be a 
marker for airway inflammation in COPD.   
Nitric Oxide: General Overview 
NO is associated with airway inflammation in asthma and is key to evaluating, 
managing, and predicting outcomes in asthma patients (Beg et al., 2009). NO may have a 
positive association with COPD, considering that inflammation of the airway is found in 
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all forms of COPD (Beg et al., 2009). Inflammation may be present in the airways, lungs, 
and pulmonary blood vessels. FENO is a noninvasive, time-saving, highly reproducible, 
and cost effective method for assessing inflammation (Bazeghi et al., 2011; Beg et al., 
2009). This study will investigate eNO as a potential marker for airway inflammation in 
COPD.  
Current research focuses on analyzing NO, eNO, FENO, NO in the alveolar 
region (CalvNO) and NO in the bronchial region (JawNO). NO is the most basic form 
and can be separated into alveolar and bronchial.  Most past research focuses on eNO or 
FENO; however, alveolar and bronchial NO studies are increasing. 
NO readings are reproducible from one day to the next in healthy individuals and 
in patients with stable COPD (Rouhos et al., 2011).  In addition, comparisons of NO 
exhaled in one breath and EBC at varying flow rates found no significant difference due 
to sampling technique (Lehouck et al., 2010). NO levels increase during periods of 
exacerbation (Agustí, Villaverde, Togores, & Bosch, 1999; Bhowmik et al., 2005; Liu et 
al., 2007).  Other factors that affect NO levels in EBC include suffering from the 
common cold, eating NO-rich foods, working at certain occupations, and smoking 
tobacco.  The amount of NO depends upon the frequency, duration, and the time at which 
the NO readings were taken in relation to the above factors.  In addition, NO 
measurements may differ significantly depending on the diagnostic device (Borrill et al., 
2006; Korn, Telke, Kornmann, & Buhl, 2010). 
Research has shown that NO levels differ between healthy smokers and smokers 
diagnosed with COPD.  However, data was inconclusive when analyzing the effects of 
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smoking in the following subgroups of COPD patients: smokers, ex-smokers and healthy 
COPD patients (Beg et al., 2009; Lehouck et al., 2010). One study demonstrated that 
FENO levels were elevated in COPD patients compared to controls (56 +/- 28.01 vs. 
22.00 +/- 6.69, p = 0.0001; Beg et al., 2009). However, the sample size was low, with a 
total of 14 COPD patients included in the sample. Other factors which may have affected 
the study were that (1) all participants were male; (2) current smokers were included in 
both the COPD and the control groups; and (3) patients using steroids were included (Beg 
et al., 2009). However, another study found that eNO is significantly higher in EBC of 
chronic smokers than in nonsmokers (Liu et al., 2007). COPD-diagnosed individuals 
contained higher eNO levels in their breath than healthy controls (9.8 +/- 0.7 vs. 5.5 +/- 
0.4, p < 0.0005; Liu et al., 2007).  In addition, when comparing nonsmoking COPD 
patients with ex-smokers, COPD patients registered higher eNO levels as well (9.2 +/- 
1.2 vs. 5.7 +/- 0.5, p = 0.002; Liu et al., 2007). Another study that examined NO levels in 
smokers, ex-smokers, and nonsmoker COPD patients showed no difference in eNO levels 
(Lehouck et al., 2010).  Comparison of healthy ex-smokers and healthy smokers yielded 
similar results (3.3 +/- 0.6 vs. 3.1 +/- 0.7). COPD smokers had slightly higher eNO levels 
(2.2 +/- 0.6 vs. 2.6 +/- 0.7; Lehouck et al., 2010) than COPD ex-smokers. This study 
accounted for confounding variables such as gender, current smoking behavior, body 





Nitric Oxide: Association Between COPD and Nitric Oxide 
One study tested 91 COPD patients with emphysema and chronic bronchitis to 
determine if there was a relationship between FENO and COPD (Bazeghi et al., 2011). 
The main focus of this study was to examine flow rates of NO.  All patients had a 
smoking history and BMI was recorded. BMI readings were taken.  Patients were 
allowed to take prescribed medications up to midnight the day before the testing; 
however, oral corticosteroid therapy was stopped four weeks prior to the exam (Bazeghi 
et al., 2011). A potential confounder was the inclusion of patients with exacerbations; 
studies have shown higher eNO readings during exacerbation (Bhowmik et al., 2005).  
NO levels in patients with severe emphysema were calculated for airway wall 
concentration (Caw); alveolar concentration of NO (Calv); and D, the diffusing capacity 
of NO (DawNO).  There were no significant differences among FENO levels and any of 
these measurements, as proven by the following p-values;  p = 0.15, p = 0.22, and  p= 
0.21 respectively (Bazeghi et al., 2011). Results for a study on FENO levels and chronic 
bronchitis results were not significant, either: Caw (p = 0.31), Calv (p = 0.58), and D (p = 
0.56; Bazeghi et al., 2011).  
A second study with 151 patients—84 with COPD (55 ex-smokers and 29 
smokers) and 67 healthy controls (28 smokers and 39 smokers)—concluded that the tests 
were unable to differentiate between patients with and without COPD (Lehouck et al., 
2010). Comparison of healthy ex-smokers and healthy smokers yielded similar results 
(3.3 +/- 0.6 vs. 3.1 +/- 0.7). In a comparison of COPD ex-smokers and COPD smokers,  
COPD smokers had slightly higher results (2.2 +/- 0.6 vs. 2.6 +/- 0.7; Lehouck et al., 
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2010).  This study accounted for confounding variables such as gender, current smoking 
behavior, BMI, and age. A potential weakness was that the sample size of COPD patients 
was small (22 participants). A study of 16 COPD subjects and 8 healthy nonsmokers 
found that there was no difference between eNO readings in the two groups (Rutgers et 
al., 1999). NO excretion rates between COPD and healthy patients were observed. NO 
correlated with sputum eosinophils in patients with COPD (p = 0.009) but not with 
healthy controls (Rutgers et al., 1999).  A study comparing both online and offline 
sampling measurements for eNO found that the sampling methods did not affect eNO 
levels (Deykin, Massaro, Drazen, & Israel, 2002).  This study tested 28 healthy subjects 
and 34 asthma patients using different NO offline or online sampling techniques (p = 
0.25 to 0.98; Deykin et al., 2002). Despite several studies unable to identify a correlation 
between NO and COPD, there were two studies that reported positive results. A study 
using 81 patients (18 nonsmokers, 16 smokers, 47 COPD) found a correlation between 
NO and COPD (Brindicci et al., 2005). There was a significant negative correlation 
between CalvNO, and FEV1 against COPD patients and normal healthy smokers (r = -
0.6, p =< 0.0001). Measures of the diffusion of NO in airways (DawNO) were elevated in 
smokers compared to COPD patients. This results in a weak negative correlation between 
DawNO and FEV1 in all COPD patients and smoking subjects (r = -0.4, p = 0.006) 
(Brindicci et al., 2005). This study had a small sample size of COPD patients (n = 14).  
There was no mention of confounders (such as gender, medication, or age) affecting the 
sample population. NO readings were taken on a standard chemiluminescence analyzer 
(Brindicci et al., 2005).  
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A study with 13 current smokers with COPD, 8 ex-smokers with COPD, 12 
patients with unstable COPD, and 10 smokers with chronic bronchitis found that the 
correlation between these types of COPD patients was negative for NO levels and lung 
function as defined by FEV1  (Maziak et al., 1998).  The study found that eNO levels in 
unstable COPD was higher than in COPD ex-smokers, COPD current smokers, and 
chronic bronchitis groups (12.7 +/- 1.5, < 0.01). Unstable COPD was defined by having 
exacerbations and/or severe COPD (Maziak et al., 1998).  Exhaled NO levels more were 
elevated in COPD smokers than in individuals who smoked and had chronic bronchitis 
(4.3 +/- 0.5 vs. 2.5 +/- 0.5, p < 0.05) and higher in ex-smoking COPD patients (p < 0.01) 
(Maziak et al., 1998).  However, eNO levels demonstrated a negative association with 
FEV1 (r = -0.6, p =< 0.001; Maziak et al., 1998).  A weakness was that the GOLD 
standard was not used to categorize COPD patients, as it has been in more recent studies 
(Maziak 1998).   
Nitric Oxide: COPD and Severity 
A study using 81 patients (18 nonsmokers, 16 smokers, 47 COPD) measured 
forced expiratory NO at several expired flows and found that alveolar FENO is increased 
and has a positive correlation with COPD and GOLD severity levels (Brindicci et al., 
2005). The CalvNO increase was significant in COPD patients, resulting in a positive 
correlation between CalvNO and FEV1 in COPD patients and normal healthy smokers 
(Brindicci et al., 2005). JawNO levels were lower in smokers than in healthy nonsmoking 
controls. Results for nonsmokers and GOLD Stage I-II and GOLD Stage III-IV were 
respectively (630.3 +/- 417.7 vs. 716.2 +/- 141.7 vs. 609.4 +/- 275.0). However, levels of 
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DawNO increased in COPD patients compared with smokers and controls (GOLD Stage 
I-II at 15.7 +/- 5.1; GOLD Stage III-IV at 25.0 +/- 5.0; nonsmokers (11.0 +/- 2.5); and 
smokers (11.6 +/- 3.2; Brindicci et al., 2005).  A weak negative correlation was found 
between DawNO and FEV across all COPD and smoking subjects (r = -0.4,  p = 0.006; 
Brindicci et al., 2005).  
Conversely, a cross-sectional study that tested 64 patients (25 with bronchial 
asthma, 14 with COPD and 25 normal) found that in COPD patients, there was a negative 
correlation between FEV1/FVC ratio and the level of FENO (Beg et al., 2009).  COPD 
patients had higher FENO levels than controls (56.54 +/- 28.01 vs. 22.00 +/- 6.69, p = 
0.0001; Beg et al., 2009).  A study of 43 patients with COPD found a negative correlation 
between NO and FEV1 (r = -0.6, p < 0.001; Maziak et al., 1998). In addition, a case-
control study with 151 patients, 84 with COPD (55 ex-smokers and 29 smokers) and 67 
healthy controls (28 smokers and 39 smokers) found that there was no association 
between NO (FENO, CalvNO, JawNO) and COPD severity (Lehouck et al., 2010). A 
multivariate analysis found that gender, age, BMI, GOLD stage, and corticosteroid use 
had no effect on the study.  Rather, CalvNO was the only variable that affected the 
association (p = 0.0115; Lehouck et al., 2010). Therefore, based on current literature, the 
association between NO and COPD severity is inconclusive.    
Occupational Exposure 
 One of research aims of this dissertation was to determine if the association 
between eNO and COPD is affected by occupational exposure.  Several studies have 
reported association between eNO exposure and asthma (Demange, Bohadana, Massin, & 
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Wild, 2009; Lund, Oksne, Hamre, & Kongerud, 2000; Tossa et al., 2009; Tossa et al., 
2010).  Some studies have  examined the relationship between eNO and occupational 
exposure without reference to a specific disease outcome (Kim et al., 2003; Ulvestad et 
al., 2001). To my knowledge, no studies to date have explored whether the role of 
occupation modifies the association between eNO and COPD. Kim et al. (2003) 
examined workers exposed to metal-containing fine particles from boilermakers. The 
study found that eNO concentrations decreased over a 5-day period of when not exposed 
to the particles, with a -5.5 parts per billion (ppb) mean change (95% CI: -8.8, -2.1). In 
addition, the mean change in FEV1 and FVC exhibited the same trend for the same time 
period, -1.7 L (95% CI: -0.24, -0.09) and -0.14 L (95% CI:-0.23, -0.04) for FEV1  and 
FVC, respectively (Kim et al., 2003). One reason for the decrease in eNO was that the 
study environment contained high levels of transition metals such as iron, nickel, and 
vanadium (Kim et al., 2003), whereas other studies contained a larger amount of ambient 
air (Demange et al., 2009; Tossa et al., 2009; Tossa et al., 2010)   
The studies that demonstrated an increase in eNO with occupational exposure 
were conducted in a wide range of environments. Most of these studies examined the 
effects of eNO and occupation on asthmatics. Exhaled NO is a known biomarker for 
airway inflammation in asthmatics, and different types of occupational exposures have 
been known to affect eNO readings in asthmatics. Workers are exposed to a variety of 
factors that can affect airway hyperresponsiveness and lead to increased FENO levels 
(Demange et al., 2009).  A study of 351 bakers and hairdresser apprentices showed an 
increase in FENO associated with bronchial hyperresponsiveness (OR 2.00, 95% CI: 1.21 
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– 3.32; Tossa et al., 2010). Indoor and outdoor construction workers showed significant 
differences in FENO (8.4 +/- 1.09 vs. 5.6 +/- 1.07, p = 0.001; Ulvestad et al., 2001). 
Indoor lifeguards showed elevated FENO levels compared to outdoor lifeguards 
(Demange et al., 2009).  
Based on these studies, it appears that eNO levels change depending on the type, 
duration, and concentration of exposure. If occupation modifies of the association 
between eNO and COPD, then a public health professional using eNO as a biomarker for 
COPD might misdiagnose a person who works in a high-risk occupation as having COPD 
when in fact the eNO is related to the job and not the disease. The increase in eNO might 
be due to an increase in airway inflammation as a result of asthma. Another possibility is 
that eNO concentration, FEV1, and FVC readings may actually decrease over time, 
giving a false-positive reading when diagnosing COPD (Kim et al., 2003). Therefore, 
occupation must be taken into consideration when analyzing eNO and COPD 
associations otherwise eNO occupational exposure may confound results. 
Confounders 
Potential confounders are age, gender, medications, race, body mass index, 
tobacco smoking, having other respiratory illnesses, eating and drinking nitrogen-rich 
foods and beverages, exercising, the presence of other respiratory illnesses, and tobacco 
smoking. Age: COPD is usually detected in persons aged 40 and over because of the 
disease’s progressive nature. Younger individuals usually have less airway inflammation 
damage. As the disease progresses with age, so does severity. Therefore, age becomes a 
potential confounder if age is not matched in the sample population. Gender: In some 
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populations, COPD incidence in women (5.4 95% CI: 5.3-5.6) is higher than in men (2.8 
95% CI: 2.7-2.9;  Bang et al., 2009).  Exhaled NO in the forms of DawNO and CalvNO 
showed a significant effect of eNO when compared to COPD (p = 0.049 and 0.048 
respectively; Bazeghi et al., 2011). Therefore, gender must be matched against controls to 
ensure a representative sample. Race: Different races will have varying degrees of COPD 
and COPD severity based on socioeconomics, lifestyle, and occupation. Exercise and 
BMI: Exercising and BMI may confound results as well. Medications: Corticosteroids 
will reduce the NO levels in the body and help alleviate airway inflammation. One study 
found that patients taking inhaled steroids had significantly higher eNO levels than those 
taking little or none (8.2 +/- 1.2 vs. 5 +/- 0.4,  p =< 0.05; Maziak et al., 1998).  Therefore, 
all subjects must refrain from taking corticosteroids before testing or the results may be 
skewed. Nitrogen-rich foods and beverages: Consumption will cause nitrogen levels to 
increase during testing, so the recommendation is that individuals do not eat or drink 
several hours before testing. Other respiratory diseases: Having a cold or other 
respiratory disease such as asthma may affect eNO readings as well. Exacerbations have 
been linked to higher exhaled nitrogen oxide readings (Agustí et al., 1999). Therefore, 
patients must document the frequency and type of exacerbation. Smoking: Studies have 
demonstrated that eNO levels differ between smokers, ex-smokers, patients with COPD 
who smoke and former COPD smokers (Beg et al., 2009; Brindicci et al., 2005;  Liu et 
al., 2007).  Therefore it is important to match cases and controls for the study and 





In summary, current research is inconclusive on the association between eNO and 
COPD (emphysema and chronic bronchitis) and eNO and COPD severity. One of the 
main limitations of research to date has been the small sample sizes of COPD patients 
included in the studies. Therefore, this study included a larger sample size from past 
studies and tested the associations between eNO and COPD (emphysema and chronic 
bronchitis), Exhaled NO and COPD severity, and occupation and COPD. The 




Chapter 3: Research Method 
Introduction 
 Airway inflammation is found in all forms of COPD.  NO and NO derivatives are 
known markers of airway inflammation present in EBC.  Research has shown a 
correlation between eNO and asthma; however, association between NO derivatives, 
airway inflammation, and COPD severity is inconclusive. In this study, I analyzed the 
association between eNO and COPD to determine if eNO could be used as a biomarker 
for COPD diagnosis.  
Current noninvasive techniques such as spirometry often result in under- or 
misdiagnosis (Jochmann et al., 2010; Lehouck et al., 2010; Smidth et al., 2012; Spyratos 
et al., 2012). One major limitation of using spirometry in outpatient settings is that 
training is lacking, and the equipment requires frequent calibration. Moreover, general 
physicians are not trained to read and interpret results consistently (Holz et al., 2008).   
The findings from this study could potentially lead to the development of 
noninvasive methods and diagnostic tools to diagnose COPD in outpatient settings that 
will not have the same limitations as spirometry. This may result in early diagnosis, better 
management, and lower prevalence of late-stage COPD, thereby decreasing 
complications and mortality rates.  Because of ease of use, more primary care physicians 
are likely to adopt and use it routinely in clinical settings.     
In this study, I used NHANES 2007 to 2010 data to test three hypotheses. The 
first hypothesis posited an association between eNO and COPD, defined as a patient 
having emphysema and/or chronic bronchitis. The second hypothesis posited an 
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association between eNO and COPD severity, as defined by the GOLD standards, which 
recognize four stages of severity defined by increasing levels of airway inflammation. 
The third hypothesis posited that a person’s occupation can modify the association 
between COPD and eNO.  Environmental factors associated with employment are often 
under- or not reported in literature examining the association between eNO and COPD 
(Bazeghi et al., 2011; Brindicci et al., 2005; Lehouck et al., 2010; Liu et al., 2007).  
The Center for Disease Control and Prevention’s (CDC) National Center for 
Health Statistics (NCHS) conducts the National Health and Nutrition Examination 
Survey (NHANES), an annual study that combines interviews and physical examinations 
of over 5,000 individuals in the United States (CDC, 2013a). The sample is representative 
of the United States population, and the data are publicly available on the CDC website 
(www.cdc.gov/nhanes) for anyone to use and analyze.  
Research Design and Approach 
This cross-sectional analysis used NHANES data from 2007-2008 and 2009-2010 
to test the association between eNO and COPD. This research design was different from 
other research studies in several aspects. First, most studies evaluating the relationship 
between eNO and COPD have been small, clinical studies (Bazeghi et al., 2011;Beg et 
al., 2009; Liu et al., 2007; Robbins et al., 1996; Rutgers et al., 1999). This study used a 
large population-based data source; hence, the findings are generalizable to a broader 
population. Second, most previous research analyzed either the presence of COPD 
(yes/no) or COPD severity (a matter of degree; Bazeghi et al., 2011; Beg et al., 2009; 
Bessa et al., 2011; Bhowmik et al., 2005); this study investigated both. Finally, this is the 
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first study to my knowledge that has investigated the association between eNO and 
COPD by occupation.    
Data from this study were abstracted from the examination files listed in Tables 8 
to 16.  The total sample size for NHANES 2007 to 2010 was 20,686 (10,149 for 2007–
2008 and 10,537 for 2009–2010). The sample was restricted to adults 30 years and older, 
because COPD is a slow-progressing disease that manifests later in life. The typical cut-
off is 40 years old, because prevalence increases with age. However, this study included 
the 30-year cut-off because COPD can be present in younger patients and as shown in the 
results section, the 30 to 39-year-old category indeed had a relatively high prevalence 
(3.6%) of COPD.  
NHANES Data Set 
The NHANES program began in the 1960s and focuses on different populations 
and health topics. The program became continuous in 1999. NHANES is an ongoing, 
stratified, multistage probability program of studies that examines 5,000 civilian, 
noninstitutionalized adults and children in the United States. Fifteen counties/ locations 
are visited annually where participants are interviewed, physical examinations conducted, 
and lab tests completed. Interviews are conducted to gather demographic, socioeconomic, 
dietary, and health-related information (CDC, 2013a). The physical examinations consist 
of medical, dental, and physiological measurements (CDC, 2013a). The final component 





 NHANES data were collected from interviews, physical examinations, and 
laboratory tests. The NHANES study team consisted of a physician, medical and health 
technicians, and dietary and health interviewers. Health interviews were conducted in the 
homes of respondents by a Screener, Sample Person, and Family Interviewer. Data were 
recorded using the Blaise computer-assisted personal interview (CAPI; CDC, 2013a). 
Physical examinations were performed in equipped mobile examination centers (MEC) 
that visited each location in the country. All participants visited the MEC physician for 
exams that can take up to 3 hours each. The laboratory staff consisted of medical 
technologists and phlebotomists trained by the American Society for Clinical Pathologists 
or other organizations in standard laboratory procedures (CDC, 2013a). The medical 
technologists all held baccalaureate degrees (CDC, 2013a).  The phlebotomist had 
completed training in pediatric techniques. All MEC staff were trained in safety, subject 
privacy and confidentiality, and cardiopulmonary resuscitation. 
NHANES uses a mostly paperless system by incorporating touch-sensitive 
computer screens, an audio computer-assisted self-interview system, CAPI, computer-
assisted self-interviews, face-to-face interviews, and on-site electronic questionnaires 
(CDC, 2013a).  The MECs used automated collection procedures. Laboratory 
components were recorded directly into a computer database. Access to NHANES data is 





Sampling data combining two or more 2-year data sets must be weighted to 
ensure that the sum of the weights matches the survey population (CDC, 2013a). The 
weights used in the analysis were the examination weight (variable name: WTMEC2YR) 
and the 4-year (2007 to 2010) weights that were constructed using the following formula 
(CDC, 2013a).  
If addsrvyr in (5, 6) then MEC4YR = ½* WTMEC2YR; /*for 2007 to 2010 
*SDDSRVYR is the survey cycle variable.  In this case 5 = 2007 to 2008 and 6 = 
2009 to 2010. (CDC, 2013a) 
Sample Size Calculation 
 The sample size of 1,001 was calculated using the Stata Powerlog power analysis 
from the UCLA Statistical Consulting Group (UCLA Statistical Consulting Group 2013).  
COPD is the binary dependent variable. Subjects will have COPD and controls will not. 
Exhaled nitrogen oxide was a categorical independent variable measured in quartiles and 
tested against the binary variable COPD. The calculation assumes that p1 = 0.08 and p2 = 
0.11 (OR = 1.42) for the proportion of subjects with both exhaled nitric oxide and COPD 
data. P1 (0.08) was calculated by dividing the number of confirmed physician diagnosed 
COPD cases (n = 805) by the total sample population (n = 10,214). P2 (0.11) was 
calculated by dividing pre-bronchodilator COPD cases (n = 1,160) by the total number of 
subjects (n = 10,214).  The total sample size of 1,001 was calculated with an alpha of 





Dependent Variables: Chronic Pulmonary Obstructive Disease (COPD) and COPD 
Severity 
 In both the 2007–2008 and the 2009–2010 datasets, COPD (emphysema and 
chronic bronchitis) was determined by these two questions: “Ever told you had 
emphysema?” and ”ever told you had chronic bronchitis?” (see Table 10; CDC, 2013b, 
2013c).  The binary variable was formed by individuals with positive responses to one or 
more of these questions that were coded as 1 = yes. Individuals who responded negatively 
to both questions did not have COPD and were coded 0 = no to form a binary variable.   
COPD severity was calculated using individual prebronchodilator spirometry data 
for the COPD population from NHANES 2007 to 2010, converted from milliliters to 
liters. A ratio was calculated by dividing FEV1 by FVC. Observed values less than 70% 
were divided by predicted values and aligned to the GOLD standard to determine severity 
as Stage I, II, III, or IV for analysis. All individuals with a predicted value of FEV1/FVC 
greater than or equal to 80% were placed in Stage I and labeled as mild. Individuals with 
a ratio between less than or equal to 80% and greater than or equal to 50% were defined 
as Stage II and labeled as moderate. Stage III individuals had ratios less than 50% were 
labeled as severe/very severe. Since there were few observations for Stage III and Stage 
IV, data for these two categories were combined into one category, Stage III.  
Observed baseline measurements for FEV1 were provided in NHANES 2007 to 
2010 datasets. Predicted values were calculated by dividing the observed FEV1 value by 
the predicted FEV1 value estimated for an individual of similar age, height, gender, and 
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race, using gender- and race-specific reference equations (Hankinson, Odencrantz, & 
Fedan, 1999). A correction factor of 0.88 was applied for race/ethnicity category listed as 
“other.” (Hankinson et al., 1999). 
Independent Variable: Exhaled Nitric Oxide  
FENO readings, measured in ppb, were taken during the physical examinations, 
and the mean of two reproducible readings was recorded in the variable ENXMEAN 
(CDC, 2013d, 2013e). For the purpose of this analysis, eNO, a continuous variable, was 
converted into a categorical variable and separated into quartiles.  
Effect Modifier: Occupation 
 Occupation was as an effect-modifying variable. The type of occupation and 
length of time spent in that particular occupation may cause eNO levels to increase or 
decrease.  NHANES 2007 to 2010 included a questionnaire about whether individuals 
were currently working in or had worked in an occupation where there was a risk of NO 
exposure. Any individuals who responded positively to any of the following questions 
were considered at risk of exposure to NO and coded 1 = yes. Individuals who responded 
negatively to all of these questions were considered not at risk and coded 0 = no (CDC, 
2013f, 2013g).  The questions were as follows: 
 In any job, have you ever been exposed to dust from rock, sand, concrete, coal, 
asbestos, silica, or soil? 
 In any job, have you ever been exposed to dust from baking flours, grains, wood, 
cotton, plants, or animals? 
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 In any job, have you ever been exposed to exhaust fumes from trucks, buses, 
heavy machinery, or diesel engines? 
 In any job, have you ever been exposed to any other gases, vapors, or fumes? 
Table 13 lists the inclusion questions along with more detail from NHANES 2007 to 
2010. 
Covariate Variables 
Covariates included age, gender, race/ ethnicity, tobacco smoking, and body mass 
index; whether someone smoked in the home; whether the subject ate or drank within the 
last hour, ate nitrogen rich foods within the last 3 hours, ate nitrogen-rich vegetables 
within last 3 hours, smoked within the last hour, exercised strenuously in the last hour, 
used steroids within the last 2 days, had a cough, cold or other respiratory illness in last 7 
days, or had ever been told they had asthma. A complete list of questions is found in 
Tables 14 and 16 (CDC, 2013b, 2013c, 2013h, 2013i).  
Variables – Questions and Coding 
 In this section, I describe the NHANES dataset questions and codes in detail. All 






  Covariate data on age, gender, and race were part of “Demographic Variables and 
Sample Weights” data files DEMO_E.xpt and DEMO_F.xpt (CDC, 2013h; 2013i).  See 
Table 8. 
Table 8  
Demographic Data – Description and Coding 
Variable name Description and coding Variable type Study code 
 
RIAGENDER Gender—male and 
female 
 
Covariate Male, Female 




RIDEETH1 Race/ ethnicity— 
recode 







The emphysema and chronic bronchitis data were part of “Medical Conditions” 
documentation, data files MCQ_E.xpt and MCQ_F.xpt (CDC, 2013b; 2013c). See Table 
9. 
Table 9 
COPD Determination: 2007-2010 
Variable name Description and coding Study variable 
 
MCQ160G Ever told that you had 
emphysema? 
COPD  
MCQ160K Ever told you had chronic 
bronchitis? 




The spirometry data were part of the “Spirometry—1st Test & 2nd Test 
Bronchodilator Studies” documentation data files SPX_E.xpt and SPX_F.xpt (CDC, 
2013j; 2013k). See Table 10. 
This variable was measured using the GOLD standard that measures FEV1, and 
FVC and was expressed as a ratio of FEV1/FVC (GOLD, 2010). This study used pre-
bronchodilator spirometry testing. Measurements of FEV1 were divided by FVC for pre-
bronchodilator spirometry testing. A ratio was calculated, and a stage of severity from I 
to IV was given. Table 11 lists the variables used for the calculation. 
Table 10  
COPD Severity Determination: 2007-2010 
Variable name Description and coding 
 
Study code 
SPXNFVC Baseline FVC (mL) FVC—Spirometry 
 





Table 11  
 
COPD Severity as Defined by GOLD 
 
Severity Characterized by airflow 
limitation 
Criteria 
Mild (I) FEV1/FVC < 0.70, FEV1 
>= 80 % predicted 
At this stage, the patient 
may not be aware that their 
lung function is abnormal. 
Moderate (II) FEV1/FVC < 0.70, 50 % 
<= FEV1 <= 80 % 
predicted 
Symptoms usually progress 
at this stage, with shortness 
of breath typically developing 
on exertion. 
 
Severe (III) FEV1/FVC < 0.70, 30 %  
<= FEV1 <= 50 % 
predicted 
Shortness of breath typically 
worsens at this stage and 
often limits patient’s daily 
activities. Exacerbations are 
seen beginning at 
this stage. 
Very Severe (IV) FEV1/FVC < 0.70, <30 
% predicted or  FEV1 
<50 % predicted plus 
chronic respiratory 
failure 
At this stage, quality of life 
is very appreciably impaired, 




 Exhaled NO data was part of the “Exhaled Nitric Oxide” documentation data 
files ENX_E.xpt and ENX_F.xpt (CDC, 2013d; 2013e).  See Table12. The variable 
ENXMEAN contained two reproducible eNO measurements from each participant. The 




Table 12  
Nitric Oxide Factors: 2007-2010 
Variable name Description and coding Study code 
ENXMEAN 2 reproducible FENO 
measures (ppb) 
Exhaled nitric oxide 
 
Occupation data was part of the “Occupational—OCG Questionnaire” 
documentation data files (CDC, 2013f; CDC, 2013g).  See Table 13. Occupations with no 
risk for NO exposure were coded as 0 and those at-risk were coded as 1. Those who 
responded affirmative to any of the following questions listed in Table 13 were 
considered at-risk and coded as 1. 




Variable name Description and coding Study code 
OCQ.510 In any job have you ever been exposed 
to dust from rock, sand concrete, coal, 
asbestos, silica, or soil? 
 
Exposure to rock, 
sand, coal, etc. 
OCQ.530 In any job have you ever been exposed 
to dust from baking flours, grains, 
wood, cotton, plants, or animals? 
 
Exposure to baking 
dust, grains, cotton, 
plants, etc. 
OCQ.550 In any job have you ever been exposed 
to exhaust fumes from trucks, buses, 
heavy machinery, or diesel engines? 
 
Exposure to exhaust 
fumes, trucks, buses, 
etc. 
OCQ.570 In any job have you ever been exposed 
to any other gases, vapors, or fumes? 
Exposure to other 
gases/fumes 
 
Covariate confounders that affect NO  and COPD were part of the “Smoking – 
Cigarette Use” documentation data files SMQ_E and SMQ_F, “Exhaled Nitric Oxide” 
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documentation data files ENX_E.rpt and ENX_F.rpt, and the “Medical Conditions” 
documentation data files MCQ_E.rpt and MCQ_F.rpt (CDC, 2013b;  2013c;  2013d;  
2013e;  2013l;  2013m).  See Table 14.  
Table 14  
Covariate Confounding Questions for Nitric Oxide 
Data set code Question Study code 
ENQ040 Smoked last hour? Smoked in last hour 
ENQ050 Exercised strenuously 
last hour? 
Exercised 
ENQ060 Ate or drank last hour? Ate or drank the last 
hour 
ENQ070 Ate NO-rich vegetables, 
3 hours? 
Ate NO-rich foods 
ENQ080 Ate NO-rich meats, 3 
hours? 
Ate NO-rich foods 
ENQ090 Used oral or inhaled 
steroids, 2 days? 
Used inhaled steroids 
ENQ100 Cough, cold, resp. 
illness, 7 days? 
Respiratory illness 




Covariate data on smoking behavior was part of the “Smoking—Cigarette Use” 
documentation data files SMQ_E.xpt and SMQ_F.xpt. (CDC, 2013l; 2013m).  Smoking 
status was divided into three categories, “nonsmoker,” “current smoker,” and “ex-
smoker.” A nonsmoker was defined as any individual who had smoked fewer than 100 
cigarettes in their lifetime. Current smokers included all individuals who responded 
positively to smoking at least 100 cigarettes in a lifetime and smoking cigarettes every 
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day. Ex-smokers were defined as those who had smoked at least 100 cigarettes and who 
replied that they no longer smoked cigarettes. See Table 15.   
Table 15  
Covariate—Smoking 
Data set code Question Response Individual 
code   
Study code 
SMQ020 Smoked at least 
100 cigarettes in 
life? 
Yes SMAQUEX2 Current smokers 
SMQ020 Smoked at least 
100 cigarettes in 
life? 
No SMAQUEX2 Never smokers 
SMQ040 Do you now 
smoke 
cigarettes?  
Every day SMQ077 Current smokers 
SMQ040 Do you now 
smoke 
cigarettes? 
Some days SMD641 Current smokers 
 
 Body mass index (BMI) data was part of the “Body Measures” documentation 
data files BMX_E.xpt and BMX_F.xpt (CDC, 2013n; 2013o).  See Table 16. Body mass 
index was divided into three categories, “normal,” “medium,” and “obese.” Normal was 
defined as any individual with a body mass index of less than 25. Overweight individuals 
had a body mass index greater than or equal to 25 but less than 30. Obese individuals had 




Table 16  
Covariate—Body Mass Index (BMI) 
Data set code Question Response Individual 
code   
Study code 
BMXBMI Body Mass 
Index (kg/m**2) 
Yes BMXBMI BMI 
BMXHT Height (cm) Measurement BMXHT Height 
 
Data Analysis Plan 
Data analysis was performed using STATA/ SE 12, a software program that is 
able to manage large datasets such as those in the NHANES survey (STATA Corp). 
Calculations included descriptive statistics, the chi-square test of association for 
frequency comparison, proportional odds ration regression analysis, and subpopulation 
regression analysis to test the association between eNO and COPD and the effect of 
occupation. 
Hypothesis 1: There is an association between eNO and self-reported physician-
diagnosed COPD (defined as presence of chronic bronchitis or emphysema) among adult 
NHANES 2007 to 2010 participants. This hypothesis was tested using NHANES 2007 to 
2010 self-reported data by combining the Emphysema and Chronic Bronchitis responses 
to form the binary COPD variable. All positive responses to “Ever been told you had 
chronic bronchitis?” or “Ever been told that you had emphysema?” were used to form the 
binary COPD variable.  The variable NO was created by separating the mean average of 
individual response into quartiles. Descriptive statistics and chi-square analyses were 
conducted first. Calculations included p-values for trend to check for dose–response 
relationship, odds ratios, and corresponding 95% confidence intervals. Four models were 
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created to test the hypothesis by logistic regression analysis. The first model used an 
unadjusted univariable logistic regression analysis on all individual variables.  The 
second model was adjusted for sociodemographic variables (age, gender, race, and 
smoking status) and tested with a multivariable regression analysis. The third model was 
adjusted for factors that directly affect NO and tested using a multivariable logistic 
regression analysis. These factors were: if someone smoked in the home; if the individual 
ate or drank before the study, ate nitrogen rich meats, ate nitrogen-rich vegetables, 
smoked in the last hour; if they exercised, used steroids, had a respiratory illness, or had 
asthma. The fourth model was a multivariable regression analysis including all the 
variables listed above.  
Hypothesis 2: Increasing eNO levels are associated with increased COPD 
severity, as defined by the GOLD standard. This hypothesis was tested using NHANES 
self-reported data for 2007 to 2010 by aligning FEV1/ FVC ratios to the GOLD standard 
stages for severity, associating observed ratios less than 70% lung capacity with predicted 
values. Ratios greater than 70% lung capacity were considered normal and not contained 
in the GOLD standard. The variable eNO (in quartiles) was based on responses to the 
“FENO Measurement,” using the means of 2 reproducible measurements from each 
individual. These means were then separated into quartiles. The hypothesis was tested by 
analyzing the frequency of eNO by quartiles against the frequency of COPD severity as 
defined by GOLD Stages I, II, III, and IV in pre-bronchodilator spirometry analysis. Data 
for Stages III and IV data were few and combined into one variable, Stage III. Since the 
outcome variable, COPD severity, is an ordinal variable, the proportional odds logistic 
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regression analysis (also referred to as ordinal logistic regression analysis) was 
performed.  In the proportional odds model, the probability of a larger response is 
compared to the probability of an equal or smaller response. A univariable ordered 
logistic regressions analysis was performed first, followed by multivariable ordered 
logistic regression analyses, adjusted for all confounding variables.   
 Hypothesis 3: The association between NO and COPD is modified by occupation.  
This hypothesis was tested using NHANES 2007 to 2010 data by comparing occupation 
with eNO and COPD results.  At-risk occupations were coded as 1 and low-risk 
occupations as 0.  This variable was created with responses to the Occupation OCQ 
questionnaire (CDC, 2013f; 2013g).  The questions included: “In any job have you ever 
been exposed to dust from rock, sand, concrete, coal, asbestos, silica, or soil?”; “In any 
job have you ever been exposed to dust from baking flours, grains, wood, cotton, plants, 
or animals?”; “In any job have you ever been exposed to exhaust fumes from trucks, 
buses, heavy machinery, or diesel engines?”; and “In any job have you ever been exposed 
to any other gases, vapors, or fumes?”  To test this hypothesis, data were stratified by at-
risk occupation. A univariable analysis and a subpopulation logistic regression analysis 
were conducted. Odds ratios, along with the corresponding 95% confidence intervals, 
were computed for eNO quartiles as described earlier. 
Quality 
 NHANES quality control and quality assurance is in compliance with the 1988 
Clinical Laboratory Improvement requirements (CDC, 2013a).  Several methods were 
used to monitor the quality of the analyses performed by the NHANES contract 
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laboratories. First, the equipment and data collection in the MEC are calibrated and 
checked before the analysis of the survey data is begun (CDC, 2013a).  Second, the 
quality testing performed in the MECs included analyzing “blind” split samples collected 
during pretesting. Third, random repeat testing was completed on 5% of the samples. 
Fourth, the laboratory personnel performance was monitored by NCHS and contract 
consultants during unscheduled audits using a detailed quality assurance evaluation. 
Observations of laboratory staff and feedback were provided on equipment use, specimen 
collection and preparation, survey participant interaction, and survey protocol 
implementation (CDC, 2013a). In addition, an annual retraining session was conducted.  
Concerning data processing and preparation, NHANES has guidelines for NCHS and 
contractors that contain standards for naming variables, filling missing values, and 
handling missing records (CDC, 2013a). Comments were reviewed and recorded. Prior to 
testing, all collection materials were screened by the CDC/ NCEH, Environmental Health 
Laboratory Sciences. 
Instrumentation and Materials 
The data collection instrument for this study is secondary data from the NHANES 
2007 to 2010 data set. NHANES contains information from interviews, physical 
examinations, and laboratory results on a representative sample of noninstitutionalized 
children and adults in the United States. Data sets of four consecutive years must be 
weighted (CDC, 2013a).  Data is available for public use. More information is contained 




Ethical Considerations and Protection of Human Participants 
NHANES data is free for public use. Participant information in NHANES is 
protected by the Public Health Service Act (42 USC 242k) and Section 308(d) of that law 
(42 USC 242m), the Privacy Act of 1974 (5 USC 552A), and the Confidential 
Information Protection and Statistical Efficiency Act (PL 107-347).  There are no ethical 
concerns related to the recruitment of subjects, materials used, and data collection for this 
dissertation. All participant data is anonymous and confidential and protected by the 
CDC. Furthermore, the study was approved by the Walden University institutional 
review board under reference number 12-12-13-0157824. 
Summary 
 This quantitative study applied a hypothetico-deductive approach to analyzing the 
association between NO and COPD using NHANES 2007 to 2010 data. Research areas 
included analyzing NO and COPD (emphysema and chronic bronchitis), NO and COPD 
severity, and the effect of occupation on the association between NO levels and COPD. 




Chapter 4: Results 
 The purpose of this quantitative study was to determine the association between 
eNO and COPD. The research questions and accompanying hypotheses are listed below. 
 Research Question 1: Is there an association between eNO and COPD (chronic 
bronchitis or emphysema) in adults? 
o Hypothesis 1: There is an association between eNO and self-reported 
physician diagnosed COPD (defined as presence of chronic bronchitis or 
emphysema) among adult NHANES 2007 to 2010 participants.   
o Hypothesis 2: Increasing eNO levels are associated with increased COPD 
severity, defined by the GOLD standard. 
 Research Question 2: Does occupation modify the association between eNO and 
COPD?   
o Hypothesis 3: The association between NO and COPD is modified by 
occupation. 
I begin Chapter 4 with an overview of the descriptive characteristics and chi-
square analysis. The first hypothesis, testing the association between eNO and COPD, 
was analyzed with four models. The first model was an unadjusted univariable logistic 
regression analysis of all variables. Model 2 was adjusted for socioeconomic variables. 
Model 3 was adjusted for factors that affect NO directly. Model 4 was adjusted for all 
variables. Hypothesis 2 tested the association between eNO and COPD severity through 
pre-bronchodilator spirometry analysis.  The third hypothesis tested whether occupational 
exposure is an effect modifier of the relationship between eNO and COPD with a 
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subpopulation logistic regression analysis. Chapter 4 concludes with a summary and 
transition into Chapter 5. 
Descriptive Characteristics 
 NHANES is an annual study that combines interviews and physical 
examinations of over 5,000 individuals in the United States (CDC, 2013a). The sample is 
representative of the U.S. population (CDC, 2013a). There were 20,686 participants in 
NHANES 2007 to 2010; however, the study sample was limited to participants 30 years 
and older because COPD is rarely observed in younger age groups, resulting in a sample 
size of 10,214 for the final analysis. Women made up 52% (n = 5,230) of the sample, 
while 48% were male (n = 4,984). Non-Hispanic whites made up most of the sample at 
71% (n = 4,982), followed by non-Hispanic blacks at 11% (n = 1,951).  Nonsmokers 
made up 53% (n = 5,287) of the study sample; 27% were ex-smokers (n = 2,815), and 
20% were current smokers (n = 2,106).  Thirty-five percent of responders were 
overweight (n = 3,446) and 37% were obese (n = 4,274).   
 Exhaled NO data were provided by 81% (n = 7,474) of the sample. These results 
were grouped into quartiles (see Table 17). Frequency distribution of factors that could 
directly affect eNO levels ranged from as low as 0.6% of those reporting that they had 
exercised strenuously in the last hour to as high as 52% for those who had eaten or drunk 
within the last 3 hours before beginning the examination (Table 17). 
 Nearly 8% (n = 805) of study participants were told by a physician that they had 
COPD (emphysema or chronic bronchitis).  However, after conducting pre-
bronchodilator spirometry analysis, 1,160 were confirmed to have COPD by pre-
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bronchodilator analysis. As a result, 11.4% of the entire study population were classified 
as having Stage I (n = 608), 4.8% had Stage II (n = 478), and 0.7% had Stage III (n = 75) 
COPD (Table 17).  Forty-nine percent of study respondents (n = 4,927) worked in an at-
risk occupation with the potential for exposure to NO.  




   n (un-
weighted) weighted 
Age     
30–39 yrs. 2045 22.5 
40–49 yrs. 2057 25.0 
50–59 yrs. 1876 22.7 
60–69 yrs. 1960 15.1 
70+ yrs. 2267 14.7 
Gender     
Female 5230 52.3 
Male 4984 47.7 
Race     
Non-Hispanic White 4892 70.8 
Other Hispanic 1081 4.6 
Mexican American 1723 7.5 
Non-Hispanic Black 1951 10.9 
Other Race/ Ethnicity 477 6.2 
Smoking     
Nonsmoker 5287 53.1 
Ex-Smoker 2815 27.0 
Current Smoker 2106 19.8 
BMI     
Normal 2494 27.9 
Overweight 3446 34.8 
Obese 4274 37.4 
Factors that can directly affect NO levels     
Ate or Drank within the Last Hour  4525 51.9 
    Ate Nitrogen Rich Meats 3 Hours Before 257 3.0 
Ate Nitrogen Rich Vegetables 3 Hours Before 311 4.0 




   n (un-
weighted) weighted 
Exercised Strenuously Last Hour 61 0.6 
Used Steroids in Last 2 Days 369 4.1 
Cough, Cold, or Respiratory Illness Last 7 days 1620 15.5 
Ever Been Told you Have Asthma 1294 12.9 
Exhaled Nitric Oxide     
1st Quartile (Mean = 6.2) 2042 22.1 
2nd Quartile (Mean = 11.8) 1797 20.5 
3rd Quartile (Mean = 17.6) 1842 20.0 
4th Quartile (Mean = 36.5) 1793 18.8 
COPD   
    No 9373 92.5 
    Yes 805 7.2 
Pre-Bronchodilator 1160 11.4 
    Stage I 608 6.9 
    Stage II 477 4.8 
    Stage III & IV 75 0.7 
At-Risk Occupation     
    Not at risk 4061 42.7 
    At risk 4927 49.4 
 
Chi-Square Analysis 
 Chi-square analysis was conducted across all variables against the dependent 
variable COPD (Table 18). Overall, age was significantly associated with COPD.  The 
prevalence of COPD increased by age. It was as low as 3.6% in the 30 to 39-year-old 
category and as high as 12.5% in the 60 to 69-year-old category; it declined slightly to 
10.5% in the 70+ year old category (p < 0.001).  More women than men were diagnosed 
with COPD (4.6 and 2.7 respectively, p < 0.001). Similarly, non-Hispanic whites had the 
highest prevalence of COPD at 8.2%, followed by non-Hispanic blacks (6.2%), and other 
Hispanics (5.6%, p < 0.001). Smoking was also significantly related to COPD. Ex-
smokers had the highest prevalence (12.4%), followed by current smokers (9.6%) and 
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nonsmokers (4.1%, p < 0.001). The study respondents who were obese (BMI > = 30) had 
a higher prevalence of COPD at 8.9% (p < 0.001) than either the normal and overweight 
individuals. 
   The prevalence of COPD decreased as eNO concentrations increased by 
quartiles (p < 0.001). All of the potential confounding factors that could affect eNO levels 
were significantly associated with COPD. Finally, the study respondents who worked in 
at-risk occupations had higher prevalence of COPD than those who did not work in at-
risk occupations (8.7% vs. 5.3%, p < 0.001; Table 18). 
Table 18  
 
Chi-Square Analyses for the Association Between Various Independent Variables and 
COPD 
 
 Variable COPD p- value  
Age   
 30–39 yrs. 3.6 <0.001 
40–49 yrs. 5.8 
 50–59 yrs. 6.8 
 60–69 yrs. 12.5 
 70+ yrs. 10.5 
 Gender   
 Male 5.6 <0.001 
Female 8.7 
 Race   
 Non-Hispanic White  8.2 0.001 
Other Hispanic 5.6 
 Mexican American  2.7 
 Non-Hispanic Black 6.2 
 Other Race/ Ethnicity 5.2 
 Smoking   
 Nonsmoker 4.1 <0.001 
Ex-smoker 12.4 
 Current Smoker 9.6 
 table continues 
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 Variable COPD p- value  
BMI   
 Normal 6.4 <0.001 
Overweight 6.2 
 Obese 8.9 
 Factors that could directly affect eNO   
    Ate or Drank within the Last Hour  6.5 <0.001 
    Ate Nitrogen Rich Meats 3 Hours Before 6.4 <0.001 
    Ate Nitrogen Rich Vegetables 3 Hours Before 7.6 <0.001 
    Smoked Within the Last Hour 12.2 <0.001 
    Someone Smokes in the Home  14.2 <0.001 
    Exercised Strenuously Last Hour 4.0 <0.001 
    Used Steroids in Last 2 Days 30.9 <0.001 
    Cough, Cold, or Respiratory Illness Last 7 days 10.2 <0.001 
    Ever Been Told you Have Asthma 25.2 <0.001 
Exhaled Nitric Oxide   
    1st Quartile 8.7 <0.001 
    2nd Quartile 6.1  
    3rd Quartile 5.6  
    4th Quartile 4.8  
At-Risk Occupation    
Not at-risk  5.3 <0.001 
At risk  8.7  
 
Research Question 1: Hypothesis 1 
   Is there an association between eNO and COPD (chronic bronchitis or 
emphysema) in adults? 
Hypothesis 1: There is an association between eNO and self-reported physician 
diagnosed COPD (defined as presence of chronic bronchitis or emphysema) 
among adult NHANES 2007 to 2010 participants.  
 Four models were developed to analyze the hypothesis (Table 19). Model 1 was 
unadjusted and used odds ratios and corresponding 95% confidence intervals between 
eNO quartiles and COPD. Exhaled NO levels were grouped into quartiles: Quartile 1 
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ranged from 3.5 ppb to 9.5 ppb (mean = 6.3), Quartile 2 from 9.5 ppb to 14.5 ppb (mean 
= 11.8), Quartile 3 from 14.5 to 22.5 (mean = 17.6), and Quartile 4 ranged from 22.5 to 
301 (mean = 36.5). The odds of COPD decreased as the amount of eNO increased from 
as high as 0.68 (95% CI: 0.51–0.92) for Quartile 2 to as low as 0.53 (95% CI: 0.39–0.73) 
for Quartile 4 (Table 19). When adjusted for age, gender, race, and smoking status, all 
odds ratios became statistically nonsignificant (Model 2). The odds ratio of COPD for the 
second and the third quartiles of eNO exposure remained statistically nonsignificant for 
Models 3 and 4, and only reached statistical significance for the fourth quartile with a 
43% and 40% decline in the odds of COPD for Models 3 and 4, respectively. 
Table 19  
Hypothesis 1 - Model Comparison 
                                                                                                    COPD  
eNO Model 1 
OR (95% CI) 
p-value Model 2  
OR (95% CI) 
p-value Model 3 
OR (95% CI) 
p-value Model 4  






































Note. Model 1- unadjusted analysis of odds ratio and 95% confidence interval or OR(CIs) 
Model 2 – Model adjusted for age, gender, race, and smoking odds ratio and 95% confidence interval or OR(CIs) 
Model 3 – Model adjusted for factors that can directly affect nitrogen oxide levels (Ate or Drank within Last Hour, Ate Nitrogen Rich 
Foods within the Last 3 hours, Ate Nitrogen Rich Vegetables within Last 3 Hours, Smoked within the Last Hour, Someone Smokes in 
the Home, Exercised Strenuously Last Hour, Used Steroids within the Last 2 days, Cough, Cold or Other Respiratory Illness in Last 7 
days, Ever Been Told you had Asthma) of odds ratio and 95% confidence interval or OR(CIs) 
Model 4 – Model adjusted for age, gender, race, smoking, BMI, Ate or Drank within Last Hour, Ate Nitrogen Rich Foods within the 
Last 3 hours, Ate Nitrogen Rich Vegetables within Last 3 Hours, Smoked within the Last Hour, Someone Smokes in the Home, 
Exercised Strenuously Last Hour, Used Steroids within the Last 2 days, Cough, Cold or Other Respiratory Illness in Last 7 days, Ever 
Been Told you had Asthma of odds ratio and 95% confidence interval or OR(CIs) 
  
Research Question 1: Hypothesis 2 
Hypothesis 2: Increasing eNO levels are associated with increased COPD 
severity, defined by the GOLD standard.  
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 The GOLD standard has four stages of severity. Data for stage III and IV 
severity were limited and combined into one category, Stage III.  Hence, COPD severity 
was recategorized into Stage I (mild), Stage II (moderate), and Stage III (severe/very 
severe; see Table 20). The prevalence of pre-bronchodilator COPD was 11.4%. Quartile 
3 in Model 1 was significant (p = 0.004) but the odds ratio was far from the null (OR = 
0.52), and quartile 4 was slightly better (OR = 0.77), demonstrating that confounders had 
a profound negative association with COPD severity and eNO. All variables in Model 2 
were insignificant, and the odds ratios varied significantly. Quartile 2 (OR = 1.29, 95% 
CI: 0.80–2.10), quartile 3 (OR = 0.70, 95% CI: 0.41–1.20), and quartile 4 (OR = 1.02, 95 
% CI: 0.68–1.54). Adjusting for confounders shifted the odds ratios in a positive 
direction, demonstrating that adjusting for covariates shifted all three quartiles closer to 
the null. 
Table 20  
Hypothesis 2 - Pre-Bronchodilator Spirometry Results 
 Model 1  Model 2 
NO OR (95% CI) p-value  OR (95% CI) p-value 
1st Quartile 1.00   1.00  
2nd  Quartile 0.94 (0.64-1.38) 0.749  1.29 (0.80-2.10) 0.290 
3rd Quartile 0.52 (0.34-0.80) 0.004  0.70 (0.41-1.20) 0.185 
4th Quartile 0.77 (0.57-1.04) 0.082  1.02 (0.68-1.54) 0.907 
Note. Model 1 – Unadjusted 
Model 2 - Adjusted for age, gender, race, smoking, BMI, Ate or Drank within Last Hour, Ate Nitrogen Rich Foods within the Last 3 
hours, Ate Nitrogen Rich Vegetables within Last 3 Hours, Smoked within the Last Hour, Someone Smokes in the Home, Exercised 
Strenuously Last Hour, Used Steroids within the Last 2 days, Cough, Cold or Other Respiratory Illness in Last 7 days, Ever Been Told 




Research Question 2: Hypothesis 3 
 Does occupational exposure modify the association between eNO levels and 
COPD?  
Hypothesis 3: The association between NO and COPD is modified by occupation. 
 In the unadjusted analysis (Model 1), among those who worked in at-risk 
occupations, the odds ratio of COPD decreased from 0.78 (95% CI: = 0.56–1.12) in 
Quartile 2 to 0.54 (95% CI: = 0.39–0.76) in Quartile 4 (see Table 21). The same trend 
was not apparent for the not-at-risk group (Table 21). When adjusted for potential 
confounders, the results did not change substantially (Model 2, Table 21).  
Table 21 
  
Hypothesis 3- Association Between Nitric Oxide and COPD Stratified by At-Risk 
Occupation 
 
 At-Risk Occupation 
 Model 1 Model 2  
 Yes No Yes No 
NO OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
1st Quartile 1.00 1.00 1.00 1.00 
2nd Quartile 0.78 (0.56-1.12) 0.49 (0.25-0.99) 1.17 (0.77-1.77) 0.69 (0.29-1.64) 
3rd Quartile 0.66 (0.40-1.08) 0.58 (0.32-1.05) 0.94 (0.55-1.59) 0.83 (0.38-1.81) 
4th Quartile 0.54 (0.39-0.76) 0.52 (0.29-0.94) 0.70 (0.51-0.97) 0.52 (0.26-1.03) 
 
Note. Model 1 – unadjusted analysis. 
Model 2 - Model adjusted for age, gender, race, smoking, BMI, Ate or Drank within Last Hour, Ate Nitrogen Rich Foods within the 
Last 3 hours, Ate Nitrogen Rich Vegetables within Last 3 Hours, Smoked within the Last Hour, Someone Smokes in the Home, 
Exercised Strenuously Last Hour, Used Steroids within the Last 2 Days, Cough, Cold or other Respiratory Illness in Last 7 Days, Ever 
been told you had Asthma. 
 
Summary 
The first hypothesis tested the association between eNO and COPD. All four 
models exhibited the same odds ratio trend in that the odds ratios decreased as the 
concentration of eNO increased. The second hypothesis tested the association between 
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eNO and COPD severity based on pre-bronchodilator measurements. Pre-bronchodilator 
spirometry results showed no statistically significant relationship between eNO and 
COPD. The third hypothesis evaluated the effect modification by occupation on the 
association between NO and COPD. At-risk occupational exposure did not appear to 
modify the association between eNO and COPD in this study.  Chapter 5 interprets the 
findings and compares the results to current literature.  
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Chapter 5: Discussion, Conclusions, and Recommendations,  
Overview 
 This study was performed to investigate the association between eNO and COPD 
because airway inflammation is present in all forms of COPD and eNO is an established 
biomarker for airway inflammation in asthmatics. Therefore, there may be a link between 
eNO and COPD related airway inflammation. This study used NHANES 2007 to 2010 
data for analysis. The analysis was restricted to individuals 30 years and over because 
COPD is a progressive disease and manifests mainly in older individuals. This resulted in 
a sample size of 10,214. The first hypothesis investigated the association between eNO 
and self-reported physician-diagnosed COPD.  The second hypothesis examined the 
association between eNO and COPD severity as defined by the GOLD standard. The 
GOLD standard classifies the degree of respiratory obstruction based on spirometry data 
into four stages of severity. The greater the obstruction, the more severe the disease.  
The first research question had two hypotheses, testing the association between 
eNO and COPD. The first hypothesis tested the association between eNO and COPD 
using four different models. Model 1 used a univariable logistic regression analysis.  
Model 2 used a multiple logistic regression analysis adjusted for potential confounding 
effects of sociodemographics variables such as race, age, gender, and smoking status. 
Model 3 analyzed the association between eNO and COPD adjusted for factors that could 
directly affect eNO levels such as eating nitrogen rich foods, exercising, and taking 




The second hypothesis tested the association between eNO and COPD severity, as 
determined by pre-bronchodilator measurements, using proportional odds logistic 
regression analysis (ordinal logistic regression). Because airway inflammation increases 
as disease progression worsens, there may be a link between eNO levels and COPD 
severity. COPD severity was calculated as the ratio of FEV1/FVC and was categorized 
based on the GOLD standard into four stages: Stage I (mild), Stage II (moderate), Stage 
III (severe), and Stage IV (very severe). There were limited Stage III and Stage IV data 
available. Therefore, Stage III and IV were combined into a single category: severe/very 
severe.  
The second research question analyzed whether occupation modifies the 
association between eNO and COPD. Working in certain occupations may put 
individuals at risk of exposure to higher NO levels. Respondents who replied positively 
to being exposed to harmful gases, dusts, or fumes were considered to be working in at-
risk occupations (n = 4,927). Another 4,061 responded negatively to the same questions 
and were considered as working in not-at-risk occupations. 
  Discussion 
Research Question 1: Is There is an Association Between eNO and COPD in Adults?  
The prevalence of COPD in this study was 7.2% (n = 805) based on physician 
diagnoses. However, based on pre-bronchodilator spirometry analysis, 11.4% (n = 1,160) 
of the study population was diagnosed with some form of COPD. The prevalence of 
COPD severity was 6.9% for Stage I, 4.8% for Stage II, and 0.7% for Stage III.  These 
results are similar to the ones reported by Lindberg et al. (2006), who reported the 
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prevalence of mild, moderate, and severe GOLD-COPD as 8.2%, 5.3%, and 0.7%, 
respectively. The findings from my study further supports the argument made by earlier 
researchers that COPD is often under- or misdiagnosed in the clinical setting (Bednarek 
et al., 2008; Jochmann et al., 2010; Lehouck et al., 2010; Lindberg, Bjerg, Rönmark, 
Larsson, & Lundbäck, 2006; Smidth et al., 2012; Spyratos et al., 2012). Routine use of 
spirometry testing in outpatient settings should be encouraged to diagnose, treat, and 
manage COPD cases early in the disease process to prevent the disease from progressing 
to a later, more severe stage.    
When examining the unadjusted analysis of eNO and COPD, all eNO quartile p-
values were statistically significant (Quartile 2 p = 0.013, Quartile 3 p = 0.010, and 
Quartile 4 p < 0.001). Odds ratios decreased from 0.68 in Quartile 2 to 0.53 in Quartile 4.  
However, when adjusted for factors directly affecting eNO (Model 3) and for all 
variables (Model 4), only Quartile 4 remained statistically significant at p ≤ 0.05. These 
results demonstrate that only higher concentrations of eNO are associated with lower 
odds of COPD. The inverse relationship observed in the current study could possibly be 
because only 4% of COPD patients were reportedly using steroids prior to the spirometry 
testing during the NHANES examination and were likely to be clinically stable; eNO 
levels rise during acute exacerbations, especially in patients hospitalized with severe 
COPD (Agustí et al., 1999). Similar findings were also reported by Beg et. al. (2009) who 
found a negative correlation between FEV1/FVC ratio and eNO concentration in COPD 
patients (p = 0.028). In a small clinical study of 32 Dutch subjects (16 with COPD and 16 
controls), Rutgers et al. (1999) reported no significant difference in eNO concentrations 
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between subjects with and without COPD. Despite the small sample sizes, the results 
from the current study were consistent with the three studies mentioned before.  
Inflammation in COPD is mostly present in small airways and lung parenchyma. 
This led researchers to partition total eNO into an airway and alveolar fraction. Brindicci 
et al. (2005) found that COPD severity correlated with an increase in the alveolar fraction 
of exhaled NO, CalvNO, However, their results were not confirmed by Lehouck et al. 
(2010) and Bazeghi et al. (2011) who found no correlation between eNO, CalvNO, and 
COPD severity, consistent with the results of the current study. Hence, the findings of 
this current study confirm previous data and weaken the prospect of using eNO as a 
biomarker for COPD. 
Research Question 2: Does Occupation Modify the Association between eNO and 
COPD?  
 To my knowledge, this is the first study that has explored effect modification by 
occupational exposures. This study did not find at-risk occupations to modify the 
association between eNO and COPD.  Although the adjusted odds ratio declined as eNO 
levels increased, none of the results were statistically significant. This study defined at-
risk group as anyone who was ever exposed to a wide range of factors such as dust from 
rock, sand, asbestos, baking flours, and grains. (see Table 12). This study did not take 
into account the time between exposure and testing, duration of exposure, and amount of 
particulates, dust, or fumes the participant was exposed to, all of which could potentially 
confound the relationship between eNO and COPD.  Whether the inverse relationship, 
albeit statistically nonsignificant, observed in the current study is due to the presence of 
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relatively stable COPD patients or an artifact of data should be explored in future studies.  
Exhaled NO is a known biomarker of airway inflammation in occupational asthma 
patients  (Demange et al., 2009; Lund et al., 2000; Tossa et al., 2009; Tossa et al., 2010) 
and  occupational exposures have been shown to modify the association between eNO 
and asthma (Tossa et al., 2010). However, the results of the current study conclude that 
occupation does not modify the relationship between eNO and COPD. More studies are 
needed to confirm these findings.   
Implications for Social Change 
There were two defining questions for COPD in this study; “ever been told you 
had emphysema?” and “ever been told you had chronic bronchitis?”  Eight-hundred five 
participants replied positively to either question and were labeled as having COPD.  
COPD is often misdiagnosed or underdiagnosed in the clinical setting, primarily due to 
underutilization of spirometry in outpatient settings. This study confirms previous data 
suggesting that spirometry is more sensitive than self-report for detecting early forms of 
COPD.  Effective use of spirometry testing in outpatient settings can lead to early 
diagnosis and treatment. This will likely reduce progression to later stage COPD, fewer 
comorbidities and complications related to COPD, a decline in mortality, a decrease in 
healthcare expenditure, and will result in a healthier population. 
Limitations 
 NHANES is subject to both sampling and nonsampling errors. Interview data are 
based on self-reports and subject to error because of recall bias and the participant not 
understanding the question. Physical examination and laboratory data are subject to 
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variations in the measurements.  In addition, there is the possibility of examiner or 
physician error. In order to prevent error, detailed protocols were created and audited by 
public health professionals and the scientific community.  Problems and 
misinterpretations can be prevented by reviewing the documents, reading the data 
collection protocols and data collection instruments, and conducting descriptive 
evaluation of the data at the onset (CDC, 2013a).  Prior to data collection, the NHANES 
staff takes comprehensive training and annual refresher training courses. Selection bias 
was minimized, as NHANES uses a complex, multistage probability sampling technique 
for selection. In addition, participants who were interviewed or examined were selected 
by random subsamples or statistically defined (CDC, 2013a).  
 Because the Stata statistical software package uses listwise (casewise) deletion in 
regression analysis (i.e., if a value for one variable is missing, an entire record is 
excluded from the analysis), it has the potential to drastically reduce the sample size and 
power of a study. To overcome this limitation, an indicator category for missing values 
was created for confounding variables with 10% or more missing values. In this case, the 
confounding variables were: ate or drank in the last hour, ate NO rich meats, ate NO rich 
vegetables, performed strenuous exercise in the last hour, and used steroids.  Although 
the current study included a large number of potential confounding variables, residual 
confounding due to unmeasured variables could not be ruled out.   
 Data for GOLD Stage III and IV severity were few. To overcome this limitation, 
Stage III and IV data were combined into a single category (Stage III: severe/ very 
severe). As a result, the Stage III-IV sample size for this study was larger than that of 
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most previous studies.  Asthma and COPD can coexist, and sometimes it is difficult to 
separate them clinically (de Marco et al., 2013; Kim & Rhee, 2010). There were 366 
subjects in the current study who had both asthma and COPD. Removing asthmatics from 
the analyses did not change the results. Therefore, to maintain the appropriate power, I 
chose to leave the asthma variable in multiple logistic regression analyses as a potential 
confounder.  Lastly, due to the cross-sectional nature of the data, reverse causation cannot 
be ruled out.  
 Dissemination of Findings 
The goal is to present and publish preliminary and final results at conferences 
attended by clinicians and researchers interested in COPD.  Applications for 
presentations, poster sessions, and abstracts at several conferences will be completed and 
submitted. The two proposed conferences are the Breath Analysis Summit and the 
European Respiratory Society annual conferences to be held in 2015.  
Conclusion 
This study finds no association between eNO and COPD and COPD severity. 
There may be a correlation between high levels of eNO and COPD, but further studies 
are needed.  In addition, GOLD Stage III and IV data were limited, and a larger sample 
size of later-stage COPD severity is needed to effectively investigate the association. 
Furthermore, at-risk occupation was not found to be an effect modifier. Future studies 
that include exposure times and duration are needed to further test this association.  An 
important finding of this study is that COPD is under- or misdiagnosed in the clinical 
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setting.  Therefore, routine use of spirometry should be encouraged for diagnosis and 
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Appendix A: Effect of Covariates 
The type of covariate affects the association between eNO and COPD. Regression 
analyses showed smoking status to be significant; and, as stated above, ex-smokers had a 
higher odds ratio, so inclusion of only one type of smoker can skew results.  Studies 
adjusting only for age, race and gender, may find no association between eNO and 
COPD, as in this study sociodemographics was insignificant. Studies that include other 
covariates such as eating nitrogen rich foods 3 hours before the study, smoking 
behaviors, having another respiratory illness, and exercising before the study may or may 
not find an association between eNO and COPD depending on which factors are included 
in the study and the levels of eNO. In this group, only smoking in the home, exercising 
before the exam, taking steroids, having a respiratory illness, and having asthma were 
significant. In addition, low levels of eNO are not associated with COPD, whereas high 
levels of eNO are associated with COPD in all models except when adjusting for 
sociodemographic data only. Based on this study, neither a nitrogen-rich diet nor exercise 
was significant across all models (p > 0.05).  
Overall, the study found that the prevalence of COPD increases with age, except 
in the 70+ age category, where the odds ratios actually declined. There was a significant 
correlation between COPD and steroids across all models (p < 0.05). This confirms the 
work by Liu et al. (2007), which determined there was an association between eNO, 




Appendix B: New NHANES Sampling Methodology  
A new sampling methodology was introduced in 2007 to 200. In the past, all 
Hispanics had been oversampled compared to Mexican Americans. The 12 to 15 and 16 
to 19-year age groups were combined to form a single 12 to 19-year-old group for all 
races; and for minority groups, the 40 to 59-year groups were split into 40 to 49 and 50 to 




Appendix C: Reference Equations 
Reference equations are derived from Hankison, J. L., Odencrantz, J. R. & Fedan, K. B. 
(1999). Spirometric references values are derived from a sample of the general U.S. 
population. American Journal of Respiratory Critical Care Medicine. 159(1), 179-187. 
doi: 10.1164/ajrccm.159.1.9712108 
 
FVC Reference Equations 
Male  
 Non-Hispanic White= -0.1933+0.00064*ager-
0.000269*ager*ager+0.00018642*ht*ht 
 Non-Hispanic Black (African American) = -0.1517-
0.01821*ager+0.00016643*ht*ht 
 Mexican American = 0.2376-0.00891*ager-
0.000182*ager*ager+0.00017823*ht*ht  
 Other Race= Non-Hispanic White *0.88  
 
Female 
 Non-Hispanic White  =-0.3560+0.01870*ager-
0.000382*ager*ager+0.00014815*ht*ht  
 Non-Hispanic Black= -0.3039+0.00536*ager-
0.000265*ager*ager+0.00013606*ht*ht 
 Mexican American= 0.1210+0.00307*ager-
0.000237*ager*ager+0.00014246*ht*ht  
 Other Race = Non-Hispanic White *0.88  
 
 
FEV1 Reference Equation 
Male 
 Non-Hispanic White =0.5536-0.01303*ager-
0.000172*ager*ager+0.00014098*ht*ht  
 Non-Hispanic Black =0.3411-0.02309*ager+0.00013194*ht*ht  
 Mexican American =0.6306-0.02928*ager+0.00015104*ht*ht  





 Non-Hispanic Black= 0.3433 - 0.01283*ager-
0.000097*ager*ager+0.00010846*ht*ht 
 Mexican American= 0.4529-0.01178*ager-0.000113*ager*ager+0.00012154*ht*ht  
 Other Race= Non-Hispanic White *0.88  
100 
 
Curriculum Vitae – Colin Mitchell 
 
As of December 2014 
 
Education: 
 PhD, Public Health, Concentration in Epidemiology, Walden University, Expected 
March 2015 
 MBA, Marketing Management, Pace University, 2003   
o Member of the International Honor Society for Economics – Omicron Delta 
Epsilon 
 BA Biology, University of Delaware, 1992 
 
Scientific Experience : 
Camoleon Knowledge Brokerage, Hamburg, Germany - Chief Business Development Officer – 
September 2009 to Present 
 
Camoleon is an international consulting company that supports the business-to-business process 
in Pharmaceuticals, Biotechnology, and Medical Devices by offering smart innovative business 
solutions. My responsibilities include supporting clients with direct business development for 
unique selling propositions; collaborating with companies with sourcing and change 
management needs; and using innovation management and due diligence to help clients create 






NAMSA - Biomatech, Lyon, France-Head of European Business Development – January 2005 to 
September 2009 
 
North American Science Associates is a medical device contract research organization offering 
testing and consulting services that include but are not limited to: clinical trials, biocompatibility 
testing, efficacy studies, chemical testing, and consulting services for adherence to global 
regulatory policies. The most dominant regulatory agencies and markets were: the US Food and 
Drug Administration (FDA), the Japanese Ministry of Health Labor and Welfare (JMHLW), 
and various Notified Bodies in Europe. I was responsible for visiting and promoting our 
technical services to companies across Europe by direct visits or by presenting seminars. 
 
Ciba Specialty Chemicals  
Ciba Specialty Chemicals, Technical Sales Specialist – December 1993 to April 2000 
 
I began my career with Ciba in the quality control laboratory in the pigment division in 
Newport, DE. From there I moved into a Research and Development position creating and 
improving pigments synthesis. Afterward, I relocated to the Tarrytown, NY, office and began 
supporting the Polymer division as a technical specialist. As a technical specialist I was the first 
point of contact for polymer additive questions for US-based companies. Additional 
responsibilities involved supporting large companies including Union Carbide, Dow Chemical, 






Secret Passage – Managing Director – October 2009 to Present, Thonon-les-Bains, France  
 
Secret Passage is a consulting company focused on the educational industry. Main 
responsibilities were matching educational resources with the international school curriculum, 
including but not limited to the International Baccalaureate (IB), International Primary 
curriculum (IPC), United Kingdom National Curriculum (IGSCE), United States Curriculum, 
and general international or local curriculum in international schools throughout Europe.  
 
Follett Library and International, Chicago, IL. Educational Consultant – September 2000 to 
June 2004 in the United States and from October 2009 to April 2013 in Europe. 
 
Follett International is a global leader in school materials and educational consulting focusing 
on supporting the international classroom and library with curriculum specific products and 
services.  I began working for Follett Library in the United States, consulting with over 1,100 
schools in western Connecticut and Westchester and Bronx counties in New York. I was 
responsible for consulting with schools to match our products, such as digital resources and 
books, with the needs of the schools. After moving to France and working with North American 
Science Associates, I rejoined the international division of Follett managing Europe and the 











Presentations, Workshops, and Collaborations 
 
Scientific Presentations, Workshops, and Collaborations 
 
 
 “Live Science Management for Hire.” Presented at one of the Life Science Days held by 
Life Science Sweden, a Swedish organization and paper that focuses on the Life Sciences 
in the Nordics (2010). 
 
 Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM) in Hannover, 
Germany. Collaborated on a breath research project on behalf of VOCscan (2011). 
 
 
 "Biological Evaluation and Chemical Characterisation – new issues in development and 
evaluation of medical devices” (2008). I gave a workshop at the Medicoindustrien, a 
Danish medical device organization based in Copenhagen, Denmark.  
 
Educational Presentations and Workshops 
 
Presented at the European Council of Independent Schools (ECIS) and Swiss Group of 
Independent Schools (SGIS) 
 
·            Understanding the Dynamics of Change in the Next Generation Library Patrons 
 
·            Collection Development for the 21st Century 
 
·            MetaData Tags: Cataloging and Processing New Media 
 
·            eBooks: FollettShelf - eContent Anywhere, Anytime 
